<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Evidence-based care guideline for management of acute exacerbation of asthma in children aged 0 to 18 years.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cincinnati Children's Hospital Medical Center. Evidence-based care guideline for management of acute asthma exacerbation in children. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2010 Sep 16. 35 p.  [168 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Cincinnati Children's Hospital Medical Center. Managing an acute exacerbation of asthma. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2002 Sep 3. 21 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="HCPCS: Mental health services, not otherwise specified "/><FieldValue Value="ICD9CM: Asthma, unspecified type, with status asthmaticus  (493.91); General physical examination  (89.7)"/><FieldValue Value="MSH: Acupuncture Therapy ; Administration, Inhalation ; Adrenal Cortex Hormones ; Adrenergic beta-Agonists ; Albuterol ; Aminophylline ; Anti-Anxiety Agents ; Anti-Asthmatic Agents ; Anti-Bacterial Agents ; Asthma ; Child Health Services ; Clinical Protocols ; Complementary Therapies ; Drug Therapy, Combination ; Epinephrine ; Fluid Therapy ; Forced Expiratory Volume ; Helium ; Hospitalization ; Hypnotics and Sedatives ; Intensive Care ; Ipratropium ; Magnesium Sulfate ; Medical History Taking ; Mental Health Services ; Metered Dose Inhalers ; Multilingualism ; Nebulizers and Vaporizers ; Oximetry ; Oxygen ; Oxygen Inhalation Therapy ; Patient Discharge ; Patient Education as Topic ; Peak Expiratory Flow Rate ; Physical Examination ; Physical Therapy Modalities ; Prednisone ; Referral and Consultation ; Respiratory Function Tests ; Risk Assessment ; Social Support ; Spirometry ; Status Asthmaticus ; Terbutaline ; Theophylline "/><FieldValue Value="MTH: Acupuncture procedure ; Adrenal Cortex Hormones ; Adrenergic beta-Agonists ; Aminophylline ; Anti-Anxiety Agents ; Anti-Bacterial Agents ; Antibiotics ; Asthma ; Child Health Services ; Combination Drug Therapy ; Complementary therapies ; Discharge Planning ; Epinephrine ; Fluid Therapy ; follow-up ; Forced expiratory volume function ; Helium ; Hospitalization ; Hypnotics and Sedatives ; Inhalation Drug Administration ; intensive care ; Metered Dose Inhaler ; Metered dose inhaler therapy ; mucolytic agents ; multilingualism ; Oxygen ; Oxygen saturation measurement ; Oxygen Therapy Care ; Patient Discharge ; Patient education (procedure) ; Peak expiratory flow rate measurement ; Peak flow meter (device) ; physical examination ; Physical therapy ; Prednisone ; Pulmonary Function Test/Forced Expiratory Volume 1 ; Pulmonary function tests ; Respiratory Function Tests ; Risk Assessment ; Social support ; Status Asthmaticus ; Theophylline "/><FieldValue Value="PDQ: acupuncture ; magnesium sulfate ; physiotherapy ; prednisone ; theophylline ; therapeutic epinephrine "/><FieldValue Value="SNOMEDCT_US: Acupuncture  (44868003); Acute severe exacerbation of asthma  (708090002); Albuterol  (372897005); Albuterol  (91143003); Aminophylline  (373508009); Aminophylline  (55867006); Antiasthmatic agent  (360253007); Antibacterial agent  (346325008); Antibacterial agent  (419241000); Antibiotic  (255631004); Anxiolytic  (255635008); Anxiolytic  (373282008); Asthma  (195967001); Asthma control test score  (443117005); Beta-adrenoceptor agonist  (349920008); Beta-adrenoceptor agonist  (373227004); Complementary therapy  (225423004); Corticoid preparation  (21568003); Corticoid preparation  (79440004); Discharge planning  (371754007); Epinephrine  (387362001); Epinephrine  (65502005); Family education  (311403008); Family education  (460616007); Forced expired volume  (165041004); Helium  (90317004); Inhalation therapy procedure  (1366004); Inhaled drug administration  (243132000); Inpatient care  (394656005); Ipratropium  (108624006); Ipratropium  (372518007); Ipratropium bromide  (386881005); Magnesium sulfate  (37400007); Magnesium sulfate  (387202002); Measurement of respiratory function  (23426006); Mental health service  (708168004); Metered dose inhaler  (422059006); Metered dose inhaler  (243133005); Mucolytic agent  (372761008); Mucolytic agent  (49694007); Oxygen  (24099007); Oxygen saturation measurement  (104847001); Oxygen saturation measurement  (264598005); Oxygen therapy  (57485005); Parent education: childrearing family  (386381003); Patient discharge  (58000006); Patient education  (311401005); Peak flow meter  (334990001); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Physical therapy procedure  (91251008); Prednisone  (10312003); Prednisone  (116602009); Pulse oximeter  (448703006); Referral to pharmacist  (306362008); Risk assessment  (225338004); Spirometry  (127783003); Terbutaline  (372745006); Terbutaline  (45311002); Theophylline  (372810006); Theophylline  (66493003)"/><FieldValue Value="SPN: METER, PEAK FLOW, SPIROMETRY "/><FieldValue Value="UMD: Flowmeters, Gas, Respiratory, Peak Expiratory Flow  (15-965); Gas Delivery Units, Heliox  (24-878); Oximeters, Pulse  (17-148)"/></Field></Section><Section SecID="394" OrdBy="200" Name="Regulatory Alert"><Field FieldID="154" OrdBy="205" ID="395" Name="FDA Warning/Regulatory Alert" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse&lt;/strong&gt;: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm454141.htm&quot; title=&quot;FDA Web site&quot; target=&quot;_blank&quot;&gt;July 9, 2015 - Non-aspirin Nonsteroidal Anti-inflammatory Drugs (NSAIDS)&lt;/a&gt;: The U.S. Food and Drug Administration (FDA) is strengthening an existing label warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) increase the chance of a heart attack or stroke. Based on FDA&amp;rsquo;s comprehensive review of new safety information, FDA is requiring updates to the drug labels of all prescription NSAIDs. As is the case with current prescription NSAID labels, the Drug Facts labels of over-the-counter (OTC) non-aspirin NSAIDs already contain information on heart attack and stroke risk. FDA will also request updates to the OTC non-aspirin NSAID Drug Facts labels. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Acute exacerbation of asthma&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Allergy and Immunology" /><FieldValue Value="Emergency Medicine" /><FieldValue Value="Family Practice" /><FieldValue Value="Pediatrics" /><FieldValue Value="Pulmonary Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Nurses" /><FieldValue Value="Pharmacists" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Respiratory Care Practitioners" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To resolve the acute episode providing appropriate therapies and decreasing the use of unnecessary therapies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To decrease risk of readmission to the emergency department (ED) or inpatient unit &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To initiate or update chronic care management plan and provide a discharge patient management plan &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To provide formal care transition to chronic care provider &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To maintain and improve family satisfaction &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Inclusion&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Children experiencing an acute asthma exacerbation:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Up to 18 years of age with diagnosed asthma or high probability of asthma presentation&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;0 to 12 months: accurate diagnosis of asthma in this age range is difficult (see Attachment 1, &quot;Key Indicators for Considering a Diagnosis of Asthma&quot; and Attachment 2, &quot;Differential Diagnostic Possibilities for Asthma&quot; in the original guideline document.) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Exclusion&lt;/strong&gt;: Children:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Admitted to the intensive care unit (ICU) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Who require intubation, ventilator support or are in impending respiratory arrest &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;With bronchiolitis or conditions characterized by non-bronchodilator-responsive wheezing &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Exercise caution&lt;/strong&gt; in managing children with comorbid conditions such as:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Congenital or acquired cardiovascular disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cystic fibrosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Chronic lung disease or bronchopulmonary dysplasia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Immunodeficiency syndromes &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Diagnosis/Evaluation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Focused medical history and physical, before and as therapy is initiated &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Repeat assessments of response to therapy including clinical examination, asthma score, pulse oximetry, and lung function &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Forced expiratory volume in 1 second (FEV&lt;sub&gt;1&lt;/sub&gt;) or peak flow monitoring &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment/Management&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Initial Treatment&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Oxygen &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Short-acting inhaled beta&lt;sub&gt;2&lt;/sub&gt;-agonists &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inhalation delivery device including a metered dose inhaler (MDI) with valved holding chamber (VHC) and spacers &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inhaled ipratropium bromide &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Corticosteroids &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Magnesium sulfate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Epinephrine and terbutaline &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Heliox (not recommended for routine use) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Simultaneous multiple therapies in cases of severe asthma with respiratory distress and normal mental status &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hospital admission, consult with Pediatric Intensive Care or transport to a higher level of care, as indicated &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Inpatient Management&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Continuation of therapies initiated &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment and treatment of patients who fail to progress after 12 hours and for those who decompensate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinical protocols and pathways for consistency of care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Complementary and alternative medicines (Note: Acupuncture was considered, but not recommended) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Screening for identification of risks &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consultations&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Medical (allergist or pulmonologist or specialists in childhood asthma) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Mental health &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Social services &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Interpreter services, as needed &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Pharmacist &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Discharge preparation including patient/family education regarding medication use and when to seek care, transition planning and follow-up &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Therapies not generally recommended include:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; class=&quot;contentListFont&quot;&gt;&#xD;&#xA;    &lt;li&gt;Theophylline or aminophylline (in hospitalized patients) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Antibiotics &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Aggressive rehydration &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Chest physiotherapy, incentive spirometry, and mucolytics &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Anxiolytic and hypnotic drugs &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Oral albuterol &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Symptoms, signs, and pulmonary function &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Time to discharge after discharge criteria are met &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Time to recovery of asthma symptoms &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Number of hospital admissions &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Medication side effects &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To select evidence for critical appraisal for this guideline, the Medline, EmBase and the Cochrane databases were searched for dates of January, 2002 to November, 2009 to generate an unrefined, &quot;combined evidence&quot; database using a search strategy focused on answering clinical questions relevant to acute exacerbation of asthma and employing a combination of Boolean searching on human-indexed thesaurus terms (MeSH headings using an OVID Medline interface) and &quot;natural language&quot; searching on words in the title, abstract, and indexing terms. The citations were reduced by: eliminating duplicates, review articles, non-English articles, and adult articles. The resulting abstracts were reviewed by a methodologist to eliminate low quality and irrelevant citations. During the course of the guideline development, additional clinical questions were generated and subjected to the search process, and some relevant review articles were identified. September, 2002 was the last date for which literature was reviewed for the previous version of this guideline. The details of that review strategy are documented and maintained in an asthma literature binder. However, all previous citations were reviewed for appropriateness to this revision. Any new literature encountered for this October, 2010 version was reviewed by two or more team members and then discussed as a team.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Table of Evidence Levels&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; summary=&quot;Table of Evidence Levels&quot; cellpadding=&quot;3&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Quality Level&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;1a&amp;dagger; or 1b&amp;dagger;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review, meta-analysis, or meta-synthesis of multiple studies&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;2a or 2b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Best study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;3a or 3b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Fair study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;4a or 4b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weak study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;5a or 5b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Other: General review, expert opinion, case report, consensus report, or guideline&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;5&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Local Consensus&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&amp;dagger;a = good quality study; b = lesser quality study&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The recommendations contained in this guideline were formulated by an interdisciplinary working group which performed systematic search and critical appraisal of the literature, using the Table of Evidence Levels described in the &quot;Rating Scheme for the Strength of the Evidence&quot; field, and examined current local clinical practices.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendations have been formulated by a consensus process directed by best evidence, patient and family preference and clinical expertise. During formulation of these recommendations, the team members have remained cognizant of controversies and disagreements over the management of these patients. They have tried to resolve controversial issues by consensus where possible and, when not possible, to offer optional approaches to care in the form of information that includes best supporting evidence of efficacy for alternative choices.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Table of Recommendation Strength&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; summary=&quot;Table of Recommendation Strength&quot; cellpadding=&quot;3&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Strength&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Strongly recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;There is consensus that benefits clearly outweigh risks and burdens (or vice-versa for negative recommendations).&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;There is consensus that benefits are closely balanced with risks and burdens.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No recommendation made&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;There is a lack of consensus to direct development of a recommendation.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;&lt;strong&gt;Dimensions&lt;/strong&gt;: In determining the strength of a recommendation, the development group makes a considered judgment in a consensus process that incorporates critically appraised evidence, clinical experience, and other dimensions as listed below.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;&#xD;&#xA;            &lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Grade of the Body of Evidence &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Safety/Harm &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Health benefit to the patients (direct benefit) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Burden to patient of adherence to recommendation (cost, hassle, discomfort, pain, motivation, ability to adhere, time) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Cost-effectiveness to healthcare system (balance of cost/savings of resources, staff time, and supplies based on published studies or onsite analysis) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Directness (the extent to which the body of evidence directly answers the clinical question [population/problem, intervention, comparison, outcome]) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Impact on morbidity/mortality or quality of life &lt;/li&gt;&#xD;&#xA;            &lt;/ol&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline developers reviewed published cost analyses.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guidelines have been reviewed and approved by clinical experts not involved in the development process, distributed to senior management, and other parties as appropriate to their intended purposes.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The strength of the recommendation (strongly recommended, recommended, and no recommendation) and quality of the evidence (1a-5) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Emergency Department Management&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Initial History and Physical&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that before and as therapy is initiated, a brief, focused history and physical examination is obtained, including: (Local Consensus [5]; National Asthma Education and Prevention Program [NAEPP], 2007 [5a])&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Time of onset of current exacerbation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Current medications and allergies &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Recent frequent use of beta&lt;sub&gt;2&lt;/sub&gt;-agonists &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Risk factors for severe, uncontrolled disease (e.g., emergency department [ED] visits, admissions to the hospital and intensive care unit [ICU], and prior intubations) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Exposure to asthma triggers &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Use of peak flow with home management &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Respiratory score&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Note 1&lt;/strong&gt;: Indications of more severe exacerbation include increased anxiety, decreased level of consciousness, breathlessness, diffuse wheezing or absence of air movement, increased respiratory rate, and accessory muscle use or suprasternal retractions (see Attachment 3, &quot;Formal Evaluation of Asthma Exacerbation Severity in the ED&quot;; Attachment 4, &quot;ED Management of Asthma Exacerbations - Algorithm&quot; in the original guideline document and Recommendation #13 for severe asthma with respiratory distress below).&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Note 2&lt;/strong&gt;: Perform a more detailed history and physical assessment only after therapy has begun (NAEPP, 2007 [5a]; Camargo, Rachelefsky, &amp;amp; Schatz, 2009 [5b]).&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Note 3&lt;/strong&gt;: Patient and parental reports of medication use, peak flow values and/or environmental irritant/allergen exposure often present a more favorable description of their disease management than is actual (Dell et al., 2007 [2a]; Kamps, Roorda, &amp;amp; Brand, 2001 [2b]; Bender et al., 2000 [3b]; Rich et al., 2000 [3b]; Dozier, Aligne, &amp;amp; Schlabach, 2006 [4a]; Halterman et al., 2003 [4a]; NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that repeat assessments of response to therapy be conducted, including clinical examination, asthma score, pulse oximetry, and lung function. In children with exacerbation, no single assessment tool appears to be best for assessing severity, treatment monitoring, or predicting admission; therefore, use of one tool may not be reliable (Sole et al., 1999 [2a]; Ribeiro de Andrade, Duarte, &amp;amp; Camargos, 2007 [3a]; Keahey et al., 2002 [3a]; Local Consensus [5]; British Thoracic Society &amp;amp; Scottish Intercollegiate Guidelines Network [SIGN], 2008 [5a]; NAEPP, 2007 [5a]). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that forced expiratory volume in 1 second (FEV&lt;sub&gt;1&lt;/sub&gt;) or peak flow monitoring be &lt;em&gt;attempted&lt;/em&gt; in children over 5 years with mild to moderate exacerbations &lt;strong&gt;and&lt;/strong&gt; who currently perform peak flow with home management (NAEPP, 2007 [5a]; Camargo, Rachelefsky, &amp;amp; Schatz, 2009 [5b]).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: Pulmonary function measurements, although often difficult to obtain in children, are useful in assessing the severity of an asthma exacerbation (Gorelick et al., 2004 [3a]). If able to obtain, and measurement is &amp;lt;40% of predicted (or personal best), consider adjunct therapies or admission (NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Initial Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Oxygen&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;4&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that supplemental oxygen be started and monitored when the oxygen saturation is consistently less than 91% and to wean oxygen when saturation is higher than 94% (Geelhoed, Landau, &amp;amp; Le Souef, 1994 [3a]; British Thoracic Society &amp;amp; SIGN, 2008 [5a]; NAEPP, 2007 [5a]). &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Short-Acting Inhaled Beta&lt;sub&gt;2&lt;/sub&gt;-Agonists&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;5&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that racemic albuterol, an inhaled short-acting beta&lt;sub&gt;2&lt;/sub&gt;-agonist (SABA) be administered as the drug of choice for rapid reversal of airflow obstruction (NAEPP, 2007 [5a]; Camargo, Rachelefsky, &amp;amp; Schatz, 2009 [5b]). Modify therapy based on the early clinical response to treatments (British Thoracic Society &amp;amp; SIGN, 2008 [5a]; NAEPP, 2007 [5a]; Camargo, Rachelefsky, &amp;amp; Schatz, 2009 [5b]) (see &quot;Table 1: Aerosolized Therapies &amp;ndash; Drugs and Dosage Recommendations&quot; in the original guideline document).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: Albuterol treatments given every 10 to 20 minutes for a total of 3 doses can be given safely as initial therapy (Local Consensus [5]; British Thoracic Society &amp;amp; SIGN, 2008 [5a]; NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;6&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that &lt;strong&gt;levalbuterol not&lt;/strong&gt; be &lt;strong&gt;routinely&lt;/strong&gt; used in the treatment of acute exacerbation (Local Consensus [5]).&#xD;&#xA;    &lt;p&gt;Confusion exists regarding the selection of albuterol versus levalbuterol in the treatment of acute asthma. Although levalbuterol may prove more efficacious for some individuals, there is currently no data on how to identify these patients (Jalba, 2008 [1b]). The following information may assist in the decision to choose:&lt;/p&gt;&#xD;&#xA;    &lt;blockquote&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 1: Efficacy&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;    Levalbuterol has demonstrated comparable efficacy to albuterol for treatment of acute exacerbations in the ED and inpatient settings (Gupta &amp;amp; Singh, 2007 [1b]; Ralston et al., 2005 [2a]; Carl et al., 2003 [2a]; Andrews et al., 2009 [2b]; Hardasmalani et al., 2005 [2b]; Qureshi et al., 2005 [3a]). A large double-blind prospective trial demonstrated a 10% reduction in hospital admissions with the use of levalbuterol (Carl et al., 2003 [2a]) and a retrospective review of consecutive cases demonstrated a 4.5% reduction (Schreck &amp;amp; Babin, 2005 [4a]). The numbers needed to treat (NNT) with levalbuterol to prevent one hospital admission in these studies equals 11 and 10 respectively (Carl et al., 2003 [2a]; Schreck &amp;amp; Babin, 2005 [4a]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note: 2: Side effect reduction&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;    Difference in the reduction of adverse events such as tachycardia, tremor, or increase in blood pressure has not been demonstrated when equivalent doses of levalbuterol and albuterol have been studied (Andrews et al., 2009 [2b]). The use of racemic albuterol with metered dose inhaler (MDI) has been shown to result in lower pulse rates when compared to nebulizer (Cates, Crilly, &amp;amp; Rowe, 2006 [1a]; Mathew &amp;amp; Singh, 2008 [1b]; Deerojanawong et al., 2005 [2b]; British Thoracic Society &amp;amp; SIGN, 2008 [5a]). This may be an important consideration for children at risk for tachycardia including children with congenital heart disease or known arrhythmias (Local Consensus [5]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 3: Cost&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;    Given that there appears to be no safety advantage to the use of levalbuterol, and the ability to identify patients who have a differential treatment response, the greatly increased cost of the drug would argue against its use in the general population. Discussion of the safety and cost factors with parents may assist in the selection process (Local Consensus [5]).&lt;/p&gt;&#xD;&#xA;    &lt;/blockquote&gt;&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Inhalation Delivery Device Selection&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Devices used for the delivery of bronchodilators and inhaled corticosteroids can be equally efficacious.&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;7&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that when selecting an inhalation delivery device consideration be given to the following (Dolovich et al., 2005 [1a]; Scarfone et al., 2002 [3b]):&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Device/drug availability &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Patient ability to use the selected device correctly &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Device use with multiple medications &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Cost and reimbursement &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Drug administration time &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Convenience in both outpatient and inpatient settings &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Physician and patient preference&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Note 1&lt;/strong&gt;: In children and adolescents with acute asthma exacerbation, no significant difference exists for responses such as time to recovery of asthma symptoms, repeat visits, or hospital admissions when medications are delivered via MDI with Valved Holding Chamber (VHC) or nebulizer (Mathew &amp;amp; Singh, 2008 [1b]; Delgado et al., 2003 [2a]; Jamalvi et al., 2006 [3a]; Benito-Fernandez et al., 2004 [3a]; Yilmaz et al., 2009 [4a]). Within this guideline, a spacer is defined as a Valved Holding Chamber or &quot;delivery&quot; device that has a one-way valve inside that prevents the medicine from escaping once you have pressed down on the MDI canister (Local Consensus [5]). Spacers improve the clinical effect of inhaled medications, especially in patients unable to use an MDI properly (Lavorini &amp;amp; Fontana, 2009 [5b]). The use of large volume spacers has been recommended for any inhaled asthma drug in young children, and as a means of reducing systemic bioavailability of inhaled corticosteroids in adults and children alike (Newman, 2004 [5a]). One study has demonstrated the percent difference of drug deposition into the lung as 4.9% to 10.9% with spacer use compared to no spacer. This represents a range of approximately 52% to 87% increase in drug deposition (Vidgren &amp;amp; Paronen, 1987 [4b]).&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Note 2&lt;/strong&gt;: MDIs have been shown to shorten time to discharge from the ED, to improve pulmonary function measures, and to result in lower pulse rates when compared to nebulizer (Cates, Crilly, &amp;amp; Rowe, 2006 [1a]; Castro-Rodriguez &amp;amp; Rodrigo, 2004 [1a]; Mathew &amp;amp; Singh, 2008 [1b]; Deerojanawong et al., 2005 [2b]; Boyd &amp;amp; Stuart, 2005 [3a]; Local Consensus [5]; British Thoracic Society &amp;amp; SIGN, 2008 [5a]).&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Note 3&lt;/strong&gt;: The inhalation route for SABA administration is considered optimal. Subcutaneous SABAs (epinephrine, terbutaline) provide no proven advantage over inhaled medication (NAEPP, 2007 [5a]). Intravenous SABAs have not been shown to improve pulmonary physiology or outcomes compared to inhaled routes (Travers et al., 2001 [1a]; NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Inhaled Ipratropium Bromide&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;8&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that inhaled ipratropium be added to SABA and corticosteroid therapies for children presenting with moderate or severe acute exacerbations or when the FEV&lt;sub&gt;1&lt;/sub&gt; is &amp;lt;50% of predicted (Plotnick &amp;amp; Ducharme, 2009 [1a]; Rodrigo &amp;amp; Castro-Rodriquez, 2005 [1a]; Dotson et al., 2009 [1b]; Local Consensus [5]; British Thoracic Society &amp;amp; SIGN, 2008 [5a]; NAEPP, 2007 [5a]; Hayday &amp;amp; Stevermer, 2002 [5a]) (see &quot;Table 1: Aerosolized Therapies &amp;ndash; Drugs and Dosage Recommendations&quot; in the original guideline document).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 1&lt;/strong&gt;: Adding multiple doses (up to 3 doses) of anticholinergics to SABAs appears safe, improves lung function and avoids hospital admission in 1 of 12 school-aged children with severe exacerbation (number needed to treat [NNT] = 12) (Plotnick &amp;amp; Ducharme, 2009 [1a]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 2&lt;/strong&gt;: Although ipratropium has been shown to be efficacious in preventing hospitalizations for children with exacerbations where FEV&lt;sub&gt;1&lt;/sub&gt; is &amp;lt;50% of predicted, it has not been shown to provide significant benefit &lt;em&gt;&lt;strong&gt;after&lt;/strong&gt;&lt;/em&gt; the child is hospitalized; therefore, it is not a standard therapy to be considered in the inpatient management of acute exacerbations (Plotnick &amp;amp; Ducharme, 2009 [1a]; NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Corticosteroids&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;9&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that oral corticosteroids be administered to patients who do not respond completely to initial inhaled SABAs (Edmonds et al., 2009 [1a]; NAEPP, 2007 [5a]; Camargo, Rachelefsky, &amp;amp; Schatz, 2009 [5b]) (see &quot;Table 2: Corticosteroids &amp;ndash; Drugs and Dosage Recommendations&quot; in the original guideline document).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 1&lt;/strong&gt;: Corticosteroids speed the resolution of airflow obstruction, reduce the rate of relapse, and may reduce hospitalizations, especially if administered within one hour of presentation to the ED (Rowe et al., &quot;Early emergency,&quot; 2009 [1a]; Edmonds et al., 2009 [1a]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 2&lt;/strong&gt;: Oral prednisone has effects equivalent to those of intravenous methylprednisolone including tolerance by children (Rowe et al., &quot;Early emergency,&quot; 2009 [1a]; British Thoracic Society &amp;amp; SIGN, 2008 [5a]; NAEPP, 2007 [5a]; Camargo, Rachelefsky, &amp;amp; Schatz, 2009 [5b]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 3&lt;/strong&gt;: For treatment of acute exacerbation, insufficient evidence exists for inhaled corticosteroid therapy alone or as an additive benefit when used with systemic corticosteroids (Edmonds et al., 2009 [1a]; Schuh et al., 2006 [2b]; Nakanishi, Klasner, &amp;amp; Rubin, 2003 [2b]; NAEPP, 2007 [5a]; Camargo, Rachelefsky, &amp;amp; Schatz, 2009 [5b]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 4&lt;/strong&gt;: If the patient is on routine inhaled steroids for chronic control it is not necessary to stop their use during exacerbation. The inhaled corticosteroids can be started at any time regardless of oral dosing for the exacerbation (Local Consensus [5]; British Thoracic Society &amp;amp; SIGN, 2008 [5a]; NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 5&lt;/strong&gt;: It is recognized that many children will have problems with treatment adherence due to an oral aversion to medicine, especially bitter-tasting corticosteroid preparations. In such cases, alternatives such as intramuscularly administered dexamethasone, oral dexamethasone, and orally administered intravenous versions of corticosteroids have been proven efficacious (Rowe et al., &quot;Early emergency,&quot; 2009 [1a]; Smith et al., 2009 [1a]; Gordon, Tompkins, &amp;amp; Dayan, 2007 [2a]; Altamimi et al., 2006 [2a]; Qureshi, Zaritsky, &amp;amp; Poirier, 2001 [2a]; Greenberg, Kerby, &amp;amp; Roosevelt, 2008 [2b]; Huang et al., 2007 [2b]; Gries et al., 2000 [2b]).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Adjunctive Therapies&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Magnesium Sulfate&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;10&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended in children with moderate to severe exacerbations who are minimally responsive or unresponsive to initial treatment (SABA, oral corticosteroids, and ipratropium), that intravenous magnesium sulfate be administered (Rowe et al., &quot;Magnesium sulfate,&quot; 2009 [1a]; Mohammed &amp;amp; Goodacre, 2007 [1a]; Ciarallo, Brousseau, &amp;amp; Reinert, 2000 [2b]; British Thoracic Society &amp;amp; SIGN, 2008 [5a]) (see &quot;Table 3: Adjunctive Therapies &amp;ndash; Drugs and Dosage Recommendations&quot; in the original guideline document).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 1&lt;/strong&gt;: In patients with acute exacerbation who have been maximized on standard therapy, intravenous magnesium sulfate has been shown to reduce hospitalizations and to improve lung function without significant side effects. Possible side effects to be aware of include hypotension, hypotonia, or abnormal reflexes when given doses above that recommended for asthma (Rowe et al., &quot;Magnesium sulfate,&quot; 2009 [1a]; Mohammed &amp;amp; Goodacre, 2007 [1a]; Alter, Koepsell, &amp;amp; Hilty, 2000 [1a]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 2&lt;/strong&gt;: There is insufficient evidence regarding the use of nebulized magnesium sulfate in acute exacerbation (Blitz et al., 2009 [1b]).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Epinephrine and Terbutaline&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;11&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended for patients who are minimally responsive or responding poorly to SABA/ipratropium/systemic corticosteroid/magnesium sulfate therapies, or who are unable to tolerate aerosol treatments, that parenteral epinephrine or terbutaline be considered (NAEPP, 2007 [5a]) see &quot;Table 3: Adjunctive Therapies &amp;ndash; Drugs and Dosage Recommendations&quot; in the original guideline document). &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Heliox&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;12&quot;&gt;&#xD;&#xA;    &lt;li&gt;There is insufficient evidence and lack of consensus regarding the effectiveness of heliox in acute exacerbation of asthma to make a recommendation for its routine use (Rivera et al., 2006 [2b]; British Thoracic Society &amp;amp; SIGN, 2008 [5a]).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: Heliox-driven albuterol nebulization may be considered for patients who have life- threatening exacerbation or who remain in severe exacerbation after intensive conventional adjunctive therapy (Rodrigo et al., 2006 [1a]; Kim et al., 2005 [2b]; NAEPP, 2007 [5a]). In one small study, improvement in respiratory score and shorter ED length of stay were seen when heliox was administered in moderate and severe exacerbation (Kim et al., 2005 [2b]).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Severe Asthma with Respiratory Distress and Normal Mental Status&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;13&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that multiple therapies as described below be started simultaneously while either a consult from the Pediatric Intensive Care is requested or transport to a higher level of care is arranged (Local Consensus [5]) (see &quot;Table 3: Adjunctive Therapies &amp;ndash; Drugs and Dosage Recommendations&quot; in the original guideline document).&#xD;&#xA;    &lt;p&gt;Administer:&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Continuous albuterol &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Ipratropium bromide, up to 3 doses &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Systemic corticosteroids (dexamethasone intramuscular [IM] or methylprednisolone [IV]) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Epinephrine IM &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Magnesium sulfate IV &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Consider terbutaline IV bolus, and infusion &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Timing of Disposition from the Emergency Department&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The response to initial treatment in the ED after a period of observation is a better predictor of the need for hospitalization than is the severity of an exacerbation (NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;14&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that the current severity of the exacerbation be in the &quot;mild&quot; range when evaluating a child for discharge from ED or hospital (Local Consensus [5]) (see Attachment 3, &quot;Formal Evaluation of Asthma Exacerbation Severity in ED or Urgent Care Setting&quot;, and Attachment 4, &quot;ED Management of Asthma Exacerbations - Algorithm&quot; in the original guideline document).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 1&lt;/strong&gt;: In the ED, if initial severity is moderate or severe, then the severity assessment 1 hour after treatment is better than initial severity assessment for determining the need for hospital admission as well as for predicting the need for intensive care unit in patients initially assessed as severe (Kelly, Kerr, &amp;amp; Powell, 2004 [3a]; Local Consensus [5]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 2&lt;/strong&gt;: In acute childhood asthma, a repeat pulse oximetry of &amp;lt;92 to 94% at 1 hour after treatment better predicts need for hospitalization than the initial pulse oximetry (Kelly, Kerr, &amp;amp; Powell, 2004 [3a]; Wright et al., 1997 [3b]; Local Consensus [5]).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Inpatient Management&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;General Therapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;15&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended, with the exception of the use of anticholinergics such as ipratropium, that usual inpatient hospital management be viewed as a continuation of any therapies initiated in the ED including (NAEPP, 2007 [5a]):&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Aerosolized bronchodilators &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Oxygen &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Corticosteroids &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Initiation and continuation of controller (anti-inflammatory) agents &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Continued assessment &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Intermittent assessment of oxygen saturation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;FEV&lt;sub&gt;1&lt;/sub&gt; or peak expiratory flow (PEF) on admission, 15 to 20 minutes after bronchodilator therapy during acute phase and daily until discharge (in children &amp;gt;5 years of age if able to perform). &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Failure to Progress&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;16&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that the following care be initiated for patients who fail to progress after 12 hours of care (Local Consensus [5]):&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Notify treating healthcare provider of any child that has not progressed after 12 hours of care &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Assessment:&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Physical examination and respiratory score &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Explore reason/s for failure to progress (e.g., poor SABA responder, pneumonia or other diagnosis, suboptimal steroid dose or suboptimal frequency of administration) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Escalate plan based on assessment findings &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Treatment considerations, as indicated:&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Albuterol treatments every 10 to 20 minutes for 3 doses or continuous albuterol administered over 30 minutes, and reassess &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Chest x-ray &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Administer or re-administer IV steroid if greater than or equal to 12 hours since last dose (oral or IM if cannot acquire IV access) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Venous or capillary blood gas &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;If status is improved after treatment escalation, then reassess hourly &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;If status is not improved, discuss potential for transfer to pediatric intensive care unit (PICU) or higher level of care &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Consider subspecialty consult &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Decompensation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;17&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that the following care be initiated for the patient whose condition is assessed as decompensating from a prior stabilized state: (this is not for the patient in an obvious medical emergency for whom a medical code needs to be initiated) (Local Consensus [5]):&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Albuterol treatments every 10 to 20 minutes for a total of 3 doses or continuous albuterol over 30 minutes, and reassess &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Initiate the Medical Response Team (MRT) or the team responsible for immediate assessment of a child with a change in condition &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Notify treating healthcare provider that child is decompensating &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Assess for treatment escalation options:&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Consider other adjunctive medications&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Epinephrine IM &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Ipratropium unless previously given &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Magnesium sulfate unless previously given &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Administer or readminister steroid if indicated (oral, IM, or IV if available) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Insert IV &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Portable chest x-ray &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Prohibit eating or drinking; nothing by mouth (NPO) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Consider capillary or venous blood gas &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Consider subspecialty consult &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Reassess after treatment escalation&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;If improved, resume hourly assessment &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;If not improved, transfer to PICU or higher level of care &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Consistency of Care&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;18&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that available protocols such as clinical pathways or protocols be used, directing consistent provision of care for patients presenting with an acute asthma exacerbation (British Thoracic Society &amp;amp; SIGN, 2008 [5a]; NAEPP, 2007 [5a]). At Cincinnati Children's Hospital Medical Center, such protocol usage includes:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Asthma clinical order set &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Aerosol and oxygen protocol&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: Use of a clinical pathway or designated care providers for inpatient management has been shown to decrease length of stay, use of SABA therapy, nursing and laboratory costs, and to improve quality of care with no increase in readmission rates (Johnson et al., 2000 [2a]; McDowell et al., 1998 [2a]; Norton et al., 2007 [4a]; Wazeka et al., 2001 [4a]; Ebbinghaus &amp;amp; Bahrainwala, 2003 [4b]; Kelly et al., 2000 [4b]).&lt;/p&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Complementary and Alternative Medicine&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;19&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that the clinician ask patients/parents about all medications and treatments they are using for asthma (Local Consensus [5]; NAEPP, 2007 [5a]).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 1&lt;/strong&gt;: A high level of use of complementary and alternative medicine (CAM) has been reported in several studies: 45% of care providers reported using herbal products with their children (Lanski et al., 2003 [3a]), 63% of adolescents reported the use of complementary medicine when surveyed (Reznik et al., 2002 [3a]), and a review of literature of CAM use in asthma found the level ranged from 33% to 89% in studies of children and adolescents (Mark, 2007 [1b]). Currently there is insufficient evidence to support or refute the use of CAM therapies (Altunc, Pittler, &amp;amp; Ernst, 2007 [1a]; Hondras, Linde, &amp;amp; Jones, 2005 [1a]; Mark, 2007 [1b]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 2&lt;/strong&gt;: Patients who use herbal treatments may need caution regarding the potential for harmful ingredients in herbal treatments and interactions with asthma medications (Lanski et al., 2003 [3a]; NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;20&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that acupuncture &lt;strong&gt;&lt;em&gt;not&lt;/em&gt;&lt;/strong&gt; be used for the treatment of asthma. No evidence of an effect of acupuncture in reducing asthma symptoms has been demonstrated (McCarney et al., 2009 [1a]; Martin et al., 2002 [1a]; NAEPP, 2007 [5a]). &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;ED or Inpatient Management&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Screening&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;21&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that systematic screening be conducted using a broad assessment tool, such as Child Asthma Risk Assessment Tool (CARAT) for identification of risks including medical, environmental, adherence, financial, psychosocial or health literacy (Local Consensus [5]). The CARAT may be accessed via the following URL: &lt;a href=&quot;http://carat.asthmarisk.org&quot; title=&quot;Asthma Risk Web site&quot;&gt;http://carat.asthmarisk.org&lt;/a&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Consultations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;22&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that the need for consultations be considered at the time of presentation or as early as possible in the acute course (Local Consensus [5]).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Medical Consultation&lt;/strong&gt;: Usual indications for medical consultation (usually, a fellowship-trained allergist or pulmonologist; occasionally, other physicians who have expertise in asthma management, developed through additional training and experience) in childhood asthma include (Local Consensus [5]; NAEPP 2007 [5a]):&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;The diagnosis of asthma is in question &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Current life-threatening or severe asthma exacerbation possibly requiring medical response team (MRT) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Poor-responder or requiring escalation in routine care or unexplained deterioration &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Repeated life-threatening hospital admissions, history of intensive care admission, frequent ED visits for asthma &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Patient has required more than two bursts of oral corticosteroids in the past 12 months &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Any exacerbation requiring hospitalization in the last 12 months &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Evaluation for addition or discontinuation of long-acting beta&lt;sub&gt;2&lt;/sub&gt;-agonists (LABA) therapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Conditions complicating asthma or its diagnosis (e.g., sinusitis, nasal polyps, aspergillosis, severe rhinitis, vocal cord dysfunction, gastroesophageal reflux, and chronic obstructive pulmonary disease) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Need for extensive education and guidance on allergen avoidance, problems with adherence to therapy and poor control, or complications of therapy. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Mental Health Consultation&lt;/strong&gt;: Patients who have significant psychiatric, psychosocial, or family problems that interfere with their asthma therapy may need referral to an appropriate mental health professional for counseling or treatment.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Social Service Consultation&lt;/strong&gt;: Indications for considering social service consultation include:&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Family's social or financial difficulties might be impediments to adherence with the treatments and medical follow-up &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Family resources are compromised or uncertain &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Interpreter Services Consultation&lt;/strong&gt;: Indication for considering services:&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Family in need of language interpretation &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Pharmacist Consultation&lt;/strong&gt;: Indications for considering pharmacist consultation (where available) include review of the medication regimen of a patient admitted for asthma exacerbation.&lt;/p&gt;&#xD;&#xA;    &lt;blockquote&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: Medication regimen evaluation may include: screening for adverse drug reactions, screening for drug interactions, ensuring appropriate medication use and dosing, appropriate route of administration, appropriate dosing intervals and/or comparison of the medication reconciliation record with the current medication orders (Sanghera et al., 2006 [1a]; Kaushal et al., 2008 [3a]).&lt;/p&gt;&#xD;&#xA;    &lt;/blockquote&gt;&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Therapies Generally NOT Recommended&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;23&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that &lt;strong&gt;theophylline&lt;/strong&gt; or &lt;strong&gt;aminophylline not&lt;/strong&gt; be administered routinely in the ED or hospitalized patient because they do not appear to provide additional benefit to optimal SABA therapy (D'Avila et al., 2008 [2b]) and may increase frequency of adverse effects in acute exacerbation (Mitra et al., 2009 [1a]; British Thoracic Society &amp;amp; SIGN, 2008 [5a]; NAEPP, 2007 [5a]).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 3&lt;/strong&gt;: Patients using theophylline as outpatients may continue on their usual doses in the hospital; obtaining a therapeutic level while the child is hospitalized may be considered, because illness can affect serum levels. Additionally, a pharmacist consult may be useful for review of drug interactions (NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;24&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that &lt;strong&gt;antibiotics not&lt;/strong&gt; be used routinely for acute asthma exacerbations in the absence of an identified bacterial focus (Graham, Lasserson, &amp;amp; Rowe, 2009 [1a]; British Thoracic Society &amp;amp; SIGN, 2008 [5a]; NAEPP, 2007 [5a]; Blasi &amp;amp; Johnston, 2007 [5b]). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that &lt;strong&gt;aggressive rehydration not&lt;/strong&gt; be used routinely for acute asthma exacerbation in the absence of clinical dehydration (NAEPP, 2007 [5a]). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that &lt;strong&gt;chest physiotherapy (CPT), incentive spirometry, and mucolytics not&lt;/strong&gt; be used routinely for acute asthma exacerbations as they can trigger bronchospasm or worsen cough or air flow obstruction during an acute asthma attack (NAEPP, 2007 [5a]). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that &lt;strong&gt;anxiolytic&lt;/strong&gt; and &lt;strong&gt;hypnotic&lt;/strong&gt; drugs &lt;strong&gt;not&lt;/strong&gt; be used routinely for acute asthma exacerbations outside of an intensive care setting, as they may cause respiratory depression (NAEPP, 2007 [5a]). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that &lt;strong&gt;oral albuterol not&lt;/strong&gt; be used for acute exacerbation (Local Consensus [5]). &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Therapy Cautions/Considerations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;29&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that for therapies outlined in this section, caution and consideration be used in treatment selections (Local Consensus [5]). &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Ibuprofen&lt;/strong&gt;: In children &lt;strong&gt;&lt;em&gt;without&lt;/em&gt;&lt;/strong&gt; known aspirin induced asthma (AIA), ibuprofen may be a better choice than acetaminophen for the treatment of fever/pain in children presenting with acute asthma exacerbations. Acetaminophen has been associated with an increased risk of wheezing (Kanabar, 2007 [1a]; Karimi, Mirzaei, &amp;amp; Ahmadieh, 2006 [4a]).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In children &lt;em&gt;&lt;strong&gt;with&lt;/strong&gt;&lt;/em&gt; known AIA, it is prudent to counsel parents regarding the potential for cross-sensitivities to non-steroidal anti-inflammatory drugs (NSAIDs) (Debley et al., 2005 [1a]). This patient population demonstrates less cross-sensitivity to acetaminophen.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Cross-Sensitivities (Jenkins, Costello, &amp;amp; Hodge, 2004 [1a]):&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Ibuprofen &amp;le;400mg, 98% &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Naproxen &amp;le;100mg, 100% &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diclofenac &amp;le;40mg, 93% &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Acetaminophen &amp;ge;500mg, 7% &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Long-Acting Beta&lt;sub&gt;2&lt;/sub&gt;-Agonists&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Epidemiological evidence suggests a link between long-acting beta&lt;sub&gt;2&lt;/sub&gt;-agonists (LABAs) and increases in asthma mortality. Concern remains that symptomatic benefit from treatment with LABAs might lead to underestimation of acute attack severity and long-term use could lead to tolerance to their bronchodilator effects (Cates, Lasserson, &amp;amp; Jaeschke, &quot;Regular treatment with salmeterol,&quot; 2009 [1a], Cates, Lasserson, &amp;amp; Jaeschke, &quot;Regular treatment with formoterol,&quot; 2009 [1a]). In addition, recent analyses by the Food and Drug Administration (FDA) and others concluded that use of LABAs is associated with an increased risk of severe worsening of asthma symptoms, leading to hospitalization in both children and adults and death in some patients with asthma (Salpeter, Wall, &amp;amp; Buckley, 2010 [1a]; Walters et al., 2007 [1a]; Salpeter et al., 2006 [1a]; FDA, 2010 [5]). The FDA is requiring further studies for safety evaluation and has concluded that although these medicines play an important role in helping some patients control asthma symptoms, their use be limited to patients whose asthma cannot be controlled with inhaled corticosteroids alone (FDA, 2010 [5]). There is no good evidence as to which subpopulation would benefit or be harmed with use of a LABA. One recent study, evaluating step-up therapy in children, concluded that response to LABA was more likely to provide a better response compared to inhaled corticosteroid (ICS) or leukotriene-receptor antagonist (LTRA). However many children had a best response to ICS or LTRA step-up, highlighting the need to regularly monitor and appropriately adjust each child's asthma therapy within this level of care before further step-up (Lemanske et al., 2010 [2a]).&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Until further studies are concluded, it is suggested that all patients treated with LABA be individually evaluated to ensure that this is the best option for asthma control (Cates, Lasserson, &amp;amp; Jaeschke, &quot;Regular treatment with salmeterol,&quot; 2009 [1a], Cates, Lasserson, &amp;amp; Jaeschke, &quot;Regular treatment with formoterol,&quot; 2009 [1a]). Such evaluation may best be performed in conjunction with an asthma specialist (Local Consensus [5]) (see Recommendation #35 below for evaluation of LABA use). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Disparities in quality of care&lt;/strong&gt;: When treating children with asthma, it is important to consider the socioeconomic factors that might lead to avoidable hospitalizations and premature mortality (Cope, Unger, &amp;amp; Glazier, 2008 [4a]; Gupta, Carrion-Carire, &amp;amp; Weiss, 2006 [4a]). Special consideration of the following conditions assists in the provision of patient-centered, equitable care:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Medicaid-covered, minority children have worse asthma status (parental report) and are less likely to be using preventive, anti-inflammatory agents than white children (Ferris et al., 2006 [4a]; Lieu et al., 2002 [4a]). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Children uninsured or on Medicaid have ranked significantly lower on seven quality measures including ED utilization, prescriptions from the ED, and access to and use of a primary care provider (Lara et al., 2003 [2a]; Knudson et al., 2009 [4a]; Wilson et al., 2005 [4a]; Ferris et al., 2001 [4a]). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Black children demonstrate more likelihood to have asthma and to experience ED visits for asthma, compared with otherwise comparable white children (Flores et al., 2005 [3a]; Jones et al., 2008 [4a]). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The effect of comorbid conditions and mental illness in mothers of asthmatic children has recently been shown to impact asthma control and health services utilization related to asthma (Coughlan, Gibson, &amp;amp; Henry, 2001 [1a]; Bartlett et al., 2001 [3a]; Belamarich, 2000 [3a]; Rodriguez et al., 2002 [4a]; Shalowitz et al., 2001 [4a]; NAEPP, 2007 [5a]) (see Recommendation #22 above, Consultations, Social Services). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Discharge/Transition Preparation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Although this guideline is focused on the acute management of asthma exacerbations, it is recognized that asthma is a chronic disease. Discharge planning is intended to assist the transition from the acute exacerbation to chronic management, identifying factors within the chronic action plan that may need adjusting to prevent future exacerbations and improve long-term patient outcomes. The transition plan is expected to enhance the likelihood that the family, and ultimately the child, will become skilled in self-management of this chronic condition. Early planning is important to assure that problems with details associated with follow-up have been resolved prior to discharge.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendations for comprehensive management of chronic asthma can be found in the most recent update of the national asthma guideline (NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;30&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that planning for discharge begin when the child first presents to the ED or hospital unit (Local Consensus [5]). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that prior to discharge the patient undergo Severity Classification of chronic asthma (see Attachment 5, &quot;Severity Classification&quot; in the original guideline document). This will support a patient-centered approach to therapy (NAEPP, 2007 [5a]). Also, Severity Classification may be useful to the primary care provider in identifying children with special health care needs and facilitating care coordination (Local Consensus [5]). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that case or care management by trained health professionals be considered for patients who have poorly controlled asthma and have recurrent visits to the ED or hospital. Care-management processes are tools to improve the efficiency and quality of primary care delivery, self management, and have demonstrated a reduction in ED visits (Schulte et al., 2004 [1b]; Levy et al., 2006 [2a]; Walders et al., 2006 [2a]; Griffiths et al., 2004 [2a]; Portnoy &amp;amp; Jennings, 2006 [4a]; Rosen &amp;amp; Rodriguez, 2006 [4a]; Spiegel et al., 2006 [4a]; Wood et al., 2006 [4a]; Allcock, 2009 [4b]; Case Management Society of America [CMSA], 2010 [5]). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended, before the patient is discharged from the ED or inpatient unit, that education be provided that is tailored to the identified needs, beliefs, and learning styles of the patient and family and addresses identified patient-desired outcomes (Zorc, Scarfone, &amp;amp; Li, 2005 [2a]; Local Consensus [5]; Mansour, 2009 [5a]; British Thoracic Society &amp;amp; SIGN, 2008 [5a]; NAEPP, 2007 [5a]).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 1&lt;/strong&gt;: When usual care for asthma was compared to more intensive educational programs (provided in either the ED, hospital, home or clinic), reduction in subsequent ED visits and hospital admissions occurred in those receiving intensive education (Boyd et al., 2009 [1a]; Wolf et al., 2008 [1a]; Karnick et al., 2007 [2a]; Brown et al., 2006 [2a]; Ng et al., 2006 [2a]; Sockrider et al., 2006 [2a]). The most effective type, duration or intensity of education has not been determined (Boyd et al., 2009 [1a]; Coffman et al., 2008 [1a]; Wolf et al., 2008 [1a]; Zorc et al., 2009 [2a]). Patient-centered, specific education efforts may be more effective than general or poorly targeted interventions (Canino et al., 2008 [2a]; Forbis &amp;amp; Aligne, 2002 [2b]; NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 2&lt;/strong&gt;: Asthma education plans have been successfully implemented in busy EDs (Boychuk et al., 2006 [3a]; NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Components of education programs have not been comparatively studied; however, programs that have demonstrated improvement have included the following components: (Boyd et al., 2009 [1a]; Coffman et al., 2008 [1a]; Wolf et al., 2008 [1a])&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Etiology, prognosis, and risk factors emphasizing chronicity of condition &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Medication purpose, and when and how to use medications (Smith et al., 2008 [4a]) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Provision or updating of written asthma plan&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: Parental attitudes toward and knowledge of asthma (pathophysiology, medications, action plans, and environmental triggers) influenced adherence to prescribed asthma medications and action plans in several studies (Jones et al., 2002 [2a]; Douglass et al., 2002 [2b]; NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Identification of environmental triggers for prevention of acute exacerbations (Lanphear et al., &quot;Residential Exposure,&quot; 2001 [4a], Lanphear et al., &quot;Contribution,&quot; 2001 [4a]) (see Attachment 6, &quot;How to Control What Makes Your Asthma Worse&quot; in the original guideline document).&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: Multifaceted allergen education and control interventions delivered in the home setting have been shown to be effective in reducing exposures to cockroach, rodent, and dust-mite allergens and associated asthma morbidity (Arshad et al., 2007 [2a]; Morgan et al., 2004 [2a]; Schonberger et al., 2004 [2a]; Moira et al., 2002 [2a]; Custovic et al., 2001 [2a]; Finn et al., 2000 [3a]; NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Demonstration of correct use of inhaler/spacer (Hussain-Rizvi, Kunkov, &amp;amp; Crain, 2009 [2b]) (see Attachment 7, &quot;How to Use Your MDI&quot; in the original guideline document) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Demonstration of peak flow technique if sending home with peak flow meter &amp;ndash; (for patients with moderate or severe persistent asthma or a history of severe exacerbations, or patients who are poor perceivers of airflow obstruction) (see Attachment 8, &quot;Peak Flow Use&quot; in the original guideline document)&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: Peak flow measurement can be a useful addition for severity assessment of an asthma exacerbation and is most useful in patients with moderate to severe persistent asthma (McMullen, Yoos, &amp;amp; Kitzman, 2002 [2a]; Yoos et al., 2002 [2a]). It can be used in short-term monitoring, acute exacerbations, and daily chronic monitoring (Goldberg et al., 2001 [4a]; Brand et al., 1999 [4a]; NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Home management of exacerbation or relapse including evaluation of early clinical signs and symptoms of airway inflammation.&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: Beginning treatment at home may avoid treatment delays, prevent exacerbations from becoming severe, and also adds to patients' sense of control over their asthma. The degree of care provided in the home depends on the patients' (or parents') abilities and experience and on the availability of emergency care (NAEPP, 2007 [5a]). Accurate evaluation of symptom severity by parents and children will assist to avoid delays in care and inappropriate home management (Garbutt et al., 2009 [2a]).&lt;/p&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Importance and purpose of follow-up appointment &amp;ndash; explore action plan, evaluate patient goal attainment, identify barriers to meeting activity goals, identify potential treatment adjustments to help meet goals and prevent future exacerbations (Zorc, Scarfone, &amp;amp; Li, 2005 [2a]; Zorc et al., 2003 [2a]; Flores et al., 2005 [3a]):&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Schedule before discharge for hospitalized patient 1 to 5 days after discharge &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Contact primary care provider before discharge from ED &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Importance of continual and consistent care in outpatient setting, partnering with primary care provider to tailor interventions toward the child's goals for activity &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Provision of asthma specialists resource information if indicated &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;34&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that SABAs be used at home on an as-needed basis after recovery from an acute asthma exacerbation (Walters &amp;amp; Walters, 2002 [1a]; NAEPP, 2007 [5a]). If patient's need is greater than 6 puffs every 3 to 4 hours by 24 to 48 hours after discharge provide family with instruction to seek medical care (Local Consensus [5]). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that if a LABA was in use before admission, it be suspended during hospitalization for exacerbation and the patient be evaluated for continuation of therapy after discharge (Local Consensus [5]; British Thoracic Society &amp;amp; SIGN, 2008 [5a]).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 1&lt;/strong&gt;: There is no evidence that continuing a LABA during exacerbation is beneficial and concern remains regarding harm with its continued use.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 2&lt;/strong&gt;: The beneficial effects of LABA in combination therapy for the patients who require more therapy than low-dose ICS alone to control asthma need to be weighed against the potential increased risk of severe exacerbations, associated with the daily use of LABAs in some patients (Cates, Lasserson, &amp;amp; Jaeschke, &quot;Regular treatment with salmeterol,&quot; 2009 [1a], Cates, Lasserson, &amp;amp; Jaeschke, &quot;Regular treatment with formoterol,&quot; 2009 [1a]; Nelson et al., 2006 [2a]; NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Consider consultation with an asthma specialist for questions regarding continuation of LABA following hospital discharge (Local Consensus [5]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 3&lt;/strong&gt;: In February of 2010 the FDA announced new safety controls for LABAs as follows:&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;&quot;LABAs are contraindicated without the use of an asthma controller medication such as inhaled corticosteroid, and should not be used alone&quot; (FDA, 2010 [5]; NAEPP, 2007 [5a]). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;&quot;LABAs ought to only be used long-term in patients whose asthma cannot be adequately controlled on other asthma controller medications&quot; (FDA, 2010 [5]). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;&quot;LABAs ought to only be used for the shortest duration of time required to achieve control of asthma symptoms and discontinued, if possible, once asthma control is achieved&quot; (FDA, 2010 [5]). &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 4&lt;/strong&gt;: Of the adjunctive therapies available, LABAs are the preferred therapy to combine with ICS in youths &amp;ge;12 years of age and adults (NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 5&lt;/strong&gt;: For patients &amp;ge;5 years of age who have moderate persistent asthma or asthma inadequately controlled on low-dose ICS, the option to increase the ICS dose may be given equal weight to the option of adding LABA (NAEPP, 2007 [5a]). A recent study suggests that patients are most likely to have a differential response to the addition of LABA to low dose ICS compared to increasing ICS or adding a leukotriene receptor antagonist. However, the safety of long term use of LABA remains uncertain (Lemanske et al., 2010 [2a]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 6&lt;/strong&gt;: For patients &amp;ge;5 years of age who have severe persistent asthma or asthma inadequately controlled, the combination of LABA and ICS is the preferred therapy (NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note 7&lt;/strong&gt;: For patients &amp;lt;4 years of age, there is insufficient evidence for use of a LABA. These drugs are not labeled for use in this age group. Consider consultation with an asthma specialist for questions regarding this subset of asthma patients before adding LABA therapy (Local Consensus [5]; NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;36&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that patients already on ICS continue ICS therapy after discharge from ED or inpatient setting. Consider initiating ICS for patients with persistent asthma if not already receiving (British Thoracic Society &amp;amp; SIGN, 2008 [5a]; NAEPP, 2007 [5a]).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: Initiating ICS at discharge for patients not already on ICS has demonstrated a decreased risk of subsequent ED visits for patients with persistent asthma (Sin &amp;amp; Man, 2002 [4a]; NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;37&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended, when possible, that long term controller medications and medicines to complete exacerbation therapy are provided to the patient prior to discharge (Qureshi, Zaritsky, &amp;amp; Poirier, 2001 [2a]; Cooper &amp;amp; Hickson, 2001 [4a]).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: Prescriptions are not always filled after discharge (Qureshi, Zaritsky, &amp;amp; Poirier, 2001 [2a]; Cooper &amp;amp; Hickson, 2001 [4a]). Outcomes demonstrated from prescriptions not filled have been an increase in missed school and work days (Qureshi, Zaritsky, &amp;amp; Poirier, 2001 [2a]). It is also believed that providing medicines will result in decrease readmission rates (Local Consensus [5]; NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;38&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that patients have a written plan that reflects adjustments necessary due to the current exacerbation and includes a stepwise approach coordinating with the child's plan for chronic management (Zemek, Bhogal, &amp;amp; Ducharme, 2008 [1a]; Bhogal, Zemek, &amp;amp; Ducharme, 2006 [1a]; NAEPP, 2007 [5a]) (see Attachment 9, &quot;Stepwise Approaching to Managing Asthma in Children&quot; in the original guideline document). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that every attempt be made to schedule the follow-up appointment before the child is discharged from the facility. When this is not possible, attempt to notify the primary care provider of the current exacerbation event (Zorc, Scarfone, &amp;amp; Li, 2005 [2a]; Zorc et al., 2003 [2a]; Local Consensus [5]; NAEPP, 2007 [5a]).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Note&lt;/strong&gt;: A significant number of patients from the Cincinnati population consider the ED their regular source of care, and a commonly held health belief is that the ED is the appropriate place to seek care for a breathing problem (Mansour, Lanphear, &amp;amp; DeWitt, 2000 [2b]). Having fewer general practice contacts in the previous year has been independently associated with an increased risk of fatal asthma, increasing the importance of the follow-up visit either with the primary care provider or asthma specialist (Local Consensus [5]; NAEPP, 2007 [5a]).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Discharge Readiness&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Ongoing assessment will provide the needed information of the patient progression to determine the readiness for discharge. Discharge readiness usually includes the following:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Child stable on therapies that can be administered at home &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Home environment is able to safely fulfill discharge plan &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sufficient knowledge of asthma to manage care at home or seek help if symptoms worsen &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Arrangements for any special medications or equipment required for home therapies are complete &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Transition plan based on admission screening is complete and reflects the patients continuum of care needs &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Follow-up care is arranged, coordinating with primary care provider or asthma specialist if indicated, and providers agree with plans. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table of Evidence Levels&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; summary=&quot;Table of Evidence Levels&quot; cellpadding=&quot;3&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Quality Level&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;1a&amp;dagger; or 1b&amp;dagger;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review, meta-analysis, or meta-synthesis of multiple studies&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;2a or 2b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Best study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;3a or 3b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Fair study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;4a or 4b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weak study design for domain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;5a or 5b&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Other: General review, expert opinion, case report, consensus report, or guideline&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;5&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Local Consensus&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&amp;dagger;a = good quality study; b = lesser quality study&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table of Recommendation Strength&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; summary=&quot;Table of Recommendation Strength&quot; cellpadding=&quot;3&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Strength&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Strongly recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;There is consensus that benefits clearly outweigh risks and burdens (or vice-versa for negative recommendations).&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;There is consensus that benefits are closely balanced with risks and burdens.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No recommendation made&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;There is a lack of consensus to direct development of a recommendation.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;&lt;strong&gt;Dimensions&lt;/strong&gt;: In determining the strength of a recommendation, the development group makes a considered judgment in a consensus process that incorporates critically appraised evidence, clinical experience, and other dimensions as listed below.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;&#xD;&#xA;            &lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Grade of the Body of Evidence &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Safety/Harm &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Health benefit to the patients (direct benefit) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Burden to patient of adherence to recommendation (cost, hassle, discomfort, pain, motivation, ability to adhere, time) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Cost-effectiveness to healthcare system (balance of cost/savings of resources, staff time, and supplies based on published studies or onsite analysis) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Directness (the extent to which the body of evidence directly answers the clinical question [population/problem, intervention, comparison, outcome]) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Impact on morbidity/mortality or quality of life &lt;/li&gt;&#xD;&#xA;            &lt;/ol&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A clinical algorithm is provided for emergency department management of asthma exacerbations.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="98" OrdBy="605" ID="425" Name="References Supporting the Recommendations" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Allcock D. Using a community respiratory service to reduce children's hospital admissions. Nurs Times. 2009 Feb 3-9;105(4):22-3. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19263772&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Altamimi S, Robertson G, Jastaniah W, Davey A, Dehghani N, Chen R, Leung K, Colbourne M. Single-dose oral dexamethasone in the emergency management of children with exacerbations of mild to moderate asthma. Pediatr Emerg Care. 2006 Dec;22(12):786-93. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17198210&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Alter HJ, Koepsell TD, Hilty WM. Intravenous magnesium as an adjuvant in acute bronchospasm: a meta-analysis. Ann Emerg Med. 2000 Sep;36(3):191-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10969219&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Altunc U, Pittler MH, Ernst E. Homeopathy for childhood and adolescence ailments: systematic review of randomized clinical trials. Mayo Clin Proc. 2007 Jan;82(1):69-75. [51 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17285788&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Andrews T, McGintee E, Mittal MK, Tyler L, Chew A, Zhang X, Pawlowski N, Zorc JJ. High-dose continuous nebulized levalbuterol for pediatric status asthmaticus: a randomized trial. J Pediatr. 2009 Aug;155(2):205-10.e1. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19464028&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Arshad SH, Bateman B, Sadeghnejad A, Gant C, Matthews SM. Prevention of allergic disease during childhood by allergen avoidance: the Isle of Wight prevention study. J Allergy Clin Immunol. 2007 Feb;119(2):307-13. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17291851&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bartlett SJ, Kolodner K, Butz AM, Eggleston P, Malveaux FJ, Rand CS. Maternal depressive symptoms and emergency department use among inner-city children with asthma. Arch Pediatr Adolesc Med. 2001 Mar;155(3):347-53. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11231800&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Belamarich PF, Luder E, Kattan M, Mitchell H, Islam S, Lynn H, Crain EF. Do obese inner-city children with asthma have more symptoms than nonobese children with asthma. Pediatrics. 2000 Dec;106(6):1436-41. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11099600&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bender B, Wamboldt FS, O'Connor SL, Rand C, Szefler S, Milgrom H, Wamboldt MZ. Measurement of children's asthma medication adherence by self report, mother report, canister weight, and Doser CT. 2000 Nov;85(5):416-21. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11101187&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Benito-Fernandez J, Gonzalez-Balenciaga M, Capape-Zache S, Vazquez-Ronco MA, Mintegi-Raso S. Salbutamol via metered-dose inhaler with spacer versus nebulization for acute treatment of pediatric asthma in the emergency department. Pediatr Emerg Care. 2004 Oct;20(10):656-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15454738&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bhogal S, Zemek R, Ducharme FM. Written action plans for asthma in children. Cochrane Database Syst Rev. 2006;3:CD005306. [118 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16856090&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Blasi F, Johnston SL. The role of antibiotics in asthma. Int J Antimicrob Agents. 2007 May;29(5):485-93. [70 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17353114&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Blitz M, Blitz S, Beasely R, Diner BM, Hughes R, Knopp JA, Rowe BH. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database Syst Rev. 2009;(4)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Boychuk RB, Demesa CJ, Kiyabu KM, Yamamoto F, Yamamoto LG, Sanderson R, Gartner B, Donovan R, Beckham S, Pang C, Fanucchi R, Chong V. Change in approach and delivery of medical care in children with asthma: results  from a multicenter emergency department educational asthma management program. Pediatrics. 2006 Apr;117(4 Pt 2):S145-51. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16777830&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Boyd M, Lasserson TJ, McKean MC, Gibson PG, Ducharme FM, Haby M. Interventions for educating children who are at risk of asthma-related emergency  department attendance. Cochrane Database Syst Rev. 2009;(2):CD001290. [203 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19370563&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Boyd R, Stuart P. Pressurised metered dose inhalers with spacers versus nebulisers for beta-agonist delivery in acute asthma in children in the emergency department. Emerg Med J. 2005 Sep;22(9):641-2. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16113185&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Brand PL, Duiverman EJ, Waalkens HJ, van Essen-Zandvliet EE, Kerrebijn KF. Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyperresponsiveness during long-term treatment with inhaled corticosteroids. Dutch CNSLD Study Group. Thorax. 1999 Feb;54(2):103-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10325912&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax. 2008 May;63(Suppl 4):iv1-121. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18463203&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Brown MD, Reeves MJ, Meyerson K, Korzeniewski SJ. Randomized trial of a comprehensive asthma education program after an emergency department visit. 2006 Jul;97(1):44-51. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16892780&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Camargo CA Jr, Rachelefsky G, Schatz M. Managing asthma exacerbations in the emergency department: summary of the National Asthma Education and Prevention Program Expert Panel Report 3 guidelines for the management of asthma exacerbations. J Emerg Med. 2009 Aug;37(2 Suppl):S6-S17. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19683665&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Canino G, Vila D, Normand SL, Acosta-Perez E, Ramirez R, Garcia P, Rand C. Reducing asthma health disparities in poor Puerto Rican children: the effectiveness of a culturally tailored family intervention. J Allergy Clin Immunol. 2008 Mar;121(3):665-70. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18061648&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr. 2003 Dec;143(6):731-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14657817&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Castro-Rodriguez JA, Rodrigo GJ. beta-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years  of age: a systematic review with meta-analysis. J Pediatr. 2004 Aug;145(2):172-7. [50 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15289762&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute  asthma. Cochrane Database Syst Rev. 2006;(2):CD000052. [67 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16625527&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2009;(2):CD006924. [131 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19370661&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2009;(3):CD006922. [173 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19588410&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ciarallo L, Brousseau D, Reinert S. Higher-dose intravenous magnesium therapy for children with moderate to severe acute asthma. Arch Pediatr Adolesc Med. 2000 Oct;154(10):979-83. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11030848&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;CMSA: Case Management Society of America. [Web site]. Little Rock (AR): Case Management Society of America (CMSA); 2010&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Coffman JM, Cabana MD, Halpin HA, Yelin EH. Effects of asthma education on children's use of acute care services: a meta-analysis. Pediatrics. 2008 Mar;121(3):575-86. [48 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18310208&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cooper WO, Hickson GB. Corticosteroid prescription filling for children covered by Medicaid following an emergency department visit or a hospitalization for asthma. Arch Pediatr Adolesc Med. 2001 Oct;155(10):1111-5.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cope SF, Ungar WJ, Glazier RH. Socioeconomic factors and asthma control in children. Pediatr Pulmonol. 2008 Aug;43(8):745-52. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18615669&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Coughlan JL, Gibson PG, Henry RL. Medical treatment for reflux oesophagitis does not consistently improve asthma control: a systematic review. Thorax. 2001 Mar;56(3):198-204. [44 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Custovic A, Simpson BM, Simpson A, Kissen P, Woodcock A. Effect of environmental manipulation in pregnancy and early life on respiratory symptoms and atopy during first year of life: a randomised trial. Lancet. 2001 Jul 21;358(9277):188-93.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;D'Avila RS, Piva JP, Marostica PJ, Amantea SL. Early administration of two intravenous bolus of aminophylline added to the standard treatment of children with acute asthma. Respir Med. 2008 Jan;102(1):156-61. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17869497&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Debley JS, Carter ER, Gibson RL, Rosenfeld M, Redding GJ. The prevalence of ibuprofen-sensitive asthma in children: a randomized controlled bronchoprovocation challenge study. J Pediatr. 2005 Aug;147(2):233-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16126056&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Deerojanawong J, Manuyakorn W, Prapphal N, Harnruthakorn C, Sritippayawan S, Samransamruajkit R. Randomized controlled trial of salbutamol aerosol therapy via metered dose inhaler-spacer vs. jet nebulizer in young children with wheezing. Pediatr Pulmonol. 2005 May;39(5):466-72. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15786440&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Delgado A, Chou KJ, Silver EJ, Crain EF. Nebulizers vs metered-dose inhalers with spacers for bronchodilator therapy to treat wheezing in children aged 2 to 24 months in a pediatric emergency department. Arch Pediatr Adolesc Med. 2003 Jan;157(1):76-80. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12517199&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Dell SD, Foty R, Becker A, Franssen E, Chapman KR. Parent-reported symptoms may not be adequate to define asthma control in children. Pediatr Pulmonol. 2007 Dec;42(12):1117-24. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17960807&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, Smaldone GC, Guyatt G. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005 Jan;127(1):335-71. [142 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15654001&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Dotson K, Dallman M, Bowman CM, Titus MO. Ipratropium bromide for acute asthma exacerbations in the emergency setting: a literature review of the evidence. Pediatr Emerg Care. 2009 Oct;25(10):687-92. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19834421&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Douglass J, Aroni R, Goeman D, Stewart K, Sawyer S, Thien F, Abramson M. A qualitative study of action plans for asthma. BMJ. 2002 Apr 27;324(7344):1003-5.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Dozier A, Aligne CA, Schlabach MB. What is asthma control? Discrepancies between parents' perceptions and official definitions. J Sch Health. 2006 Aug;76(6):215-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16918841&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ebbinghaus S, Bahrainwala AH. Asthma management by an inpatient asthma care team. Pediatr Nurs. 2003 May-Jun;29(3):177-83. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12836993&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Edmonds ML, Camargo CA, Pollack CV, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev. 2009;(4)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;FDA: New Safety Controls for Long-Acting Beta Agonists, Medications used to Treat Asthma. Rockville (MD): U.S. Food and Drug Administration; 2010. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ferris TG, Crain EF, Oken E, Wang L, Clark S, Camargo Jr CA. Insurance and quality of care for children with acute asthma. Ambul Pediatr. 2001 Sep-Oct;1(5):267-74.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ferris TG, Kuhlthau K, Ausiello J, Perrin J, Kahn R. Are minority children the last to benefit from a new technology? Technology diffusion and inhaled corticosteriods for asthma. Med Care. 2006 Jan;44(1):81-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16365616&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Finn PW, Boudreau JO, He H, Wang Y, Chapman MD, Vincent C, Burge HA, Weiss ST, Perkins DL, Gold DR. Children at risk for asthma: home allergen levels, lymphocyte proliferation, and wheeze. J Allergy Clin Immunol. 2000 May;105(5):933-42.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Flores G, Abreu M, Tomany-Korman S, Meurer J. Keeping children with asthma out of hospitals: parents' and physicians' perspectives on how pediatric asthma hospitalizations can be prevented. Pediatrics. 2005 Oct;116(4):957-65. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16199708&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Forbis SG, Aligne CA. Poor readability of written asthma management plans found in national guidelines. Pediatrics. 2002 Apr;109(4):e52. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11927725&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Garbutt J, Highstein G, Nelson KA, Rivera-Spoljaric K, Strunk R. Detection and home management of worsening asthma symptoms. 2009 Dec;103(6):469-73. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20084839&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Geelhoed GC, Landau LI, Le Souef PN. Evaluation of SaO2 as a predictor of outcome in 280 children presenting with acute asthma. Ann Emerg Med. 1994 Jun;23(6):1236-41. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8198296&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Goldberg S, Springer C, Avital A, Godfrey S, Bar-Yishay E. Can peak expiratory flow measurements estimate small airway function in asthmatic children. Chest. 2001 Aug;120(2):482-8.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Gordon S, Tompkins T, Dayan PS. Randomized trial of single-dose intramuscular dexamethasone compared with prednisolone for children with acute asthma. Pediatr Emerg Care. 2007 Aug;23(8):521-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17726409&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Gorelick MH, Stevens MW, Schultz T, Scribano PV. Difficulty in obtaining peak expiratory flow measurements in children with acute  asthma. Pediatr Emerg Care. 2004 Jan;20(1):22-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14716161&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Graham V, Lasserson TJ, Rowe BH. Antibiotics for acute asthma. Cochrane Database Syst Rev. 2009;(4)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Greenberg RA, Kerby G, Roosevelt GE. A comparison of oral dexamethasone with oral prednisone in pediatric asthma exacerbations treated in the emergency department. Clin Pediatr (Phila). 2008 Oct;47(8):817-23. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18467673&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Gries DM, Moffitt DR, Pulos E, Carter ER. A single dose of intramuscularly administered dexamethasone acetate is as effective as oral prednisone to treat asthma exacerbations in young children. J Pediatr. 2000 Mar;136(3):298-303.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Griffiths C, Foster G, Barnes N, Eldridge S, Tate H, Begum S, Wiggins M, Dawson C, Livingstone AE, Chambers M, Coats T, Harris R, Feder GS. Specialist nurse intervention to reduce unscheduled asthma care in a deprived multiethnic area: the east London randomised controlled trial for high risk asthma (ELECTRA). BMJ. 2004 Jan 17;328(7432):144. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14718266&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Gupta MK, Singh M. Evidence based review on levosalbutamol. Indian J Pediatr. 2007 Feb;74(2):161-7. [35 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17337829&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Gupta RS, Carrion-Carire V, Weiss KB. The widening black/white gap in asthma hospitalizations and mortality. J Allergy Clin Immunol. 2006 Feb;117(2):351-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16461136&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Halterman JS, McConnochie KM, Conn KM, Yoos HL, Kaczorowski JM, Holzhauer RJ, Allan M, Szilagyi PG. A potential pitfall in provider assessments of the quality of asthma control. Ambul Pediatr. 2003 Mar-Apr;3(2):102-5. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12643784&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hardasmalani MD, DeBari V, Bithoney WG, Gold N. Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr Emerg Care. 2005 Jul;21(7):415-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16027572&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hayday K, Stevermer JJ. In children hospitalized for asthma exacerbations, does adding ipratropium bromide to albuterol and corticosteroids improve outcome. J Fam Pract. 2002 Mar;51(3):280. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11978242&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hondras MA, Linde K, Jones AP. Manual therapy for asthma. Cochrane Database Syst Rev. 2005;(2):CD001002. [80 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15846609&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Huang LH, Shyur SD, Wen DC, Chang YC, Ma YC, Lin SC, Wu WC, Wu JY. Prednisolone oral solution plus inhaled procaterol for acute asthma in children:  a double-blind randomized controlled trial. Acta Paediatr Taiwan. 2007 Sep-Oct;48(5):257-62. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18254574&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hussain-Rizvi A, Kunkov S, Crain EF. Does parental involvement in pediatric emergency department asthma treatment affect home management. J Asthma. 2009 Oct;46(8):792-5. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19863282&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Jalba MS. Three generations of ongoing controversies concerning the use of short acting beta-agonist therapy in asthma: a review. J Asthma. 2008 Jan-Feb;45(1):9-18. [79 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18259990&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Jamalvi SW, Raza SJ, Naz F, Shamim S, Jamalvi SM. Management of acute asthma in children using metered dose inhaler and small volume nebulizer. J Pak Med Assoc. 2006 Dec;56(12):595-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17312651&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004 Feb 21;328(7437):434. [12 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14976098&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Johnson KB, Blaisdell CJ, Walker A, Eggleston P. Effectiveness of a clinical pathway for inpatient asthma management. Pediatrics. 2000 Nov;106(5):1006-12. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11061767&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Jones KG, Bell J, Fehrenbach C, Pearce L, Grimley D, McCarthy TP. Understanding patient perceptions of asthma: results of the Asthma Control and Expectations (ACE) survey. Int J Clin Pract. 2002 Mar;56(2):89-93.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Jones R, Lin S, Munsie JP, Radigan M, Hwang SA. Racial/ethnic differences in asthma-related emergency department visits and hospitalizations among children with wheeze in Buffalo, New York. J Asthma. 2008 Dec;45(10):916-22. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19085583&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kamps AW, Roorda RJ, Brand PL. Peak flow diaries in childhood asthma are unreliable. Thorax. 2001 Mar;56(3):180-2.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kanabar D. Ibuprofen and asthma in paediatric populations: clinical concern or clinical reality. J R Soc Med. 2007;100 Suppl :15-7. [27 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18335849&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Karimi M, Mirzaei M, Ahmadieh MH. Acetaminophen use and the symptoms of asthma, allergic rhinitis and eczema in children. Iran J Allergy Asthma Immunol. 2006 Jun;5(2):63-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17237578&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Karnick P, Margellos-Anast H, Seals G, Whitman S, Aljadeff G, Johnson D. The pediatric asthma intervention: a comprehensive cost-effective approach to asthma management in a disadvantaged inner-city community. J Asthma. 2007 Jan-Feb;44(1):39-44. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17365203&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kaushal R, Bates DW, Abramson EL, Soukup JR, Goldmann DA. Unit-based clinical pharmacists' prevention of serious medication errors in pediatric inpatients. Am J Health Syst Pharm. 2008 Jul 1;65(13):1254-60. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18574016&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Keahey L, Bulloch B, Becker AB, Pollack CV Jr, Clark S, Camargo CA Jr, Multicenter Asthma Research Collaboration (MARC) Investigators. Initial oxygen saturation as a predictor of admission in children presenting to the emergency department with acute asthma. Ann Emerg Med. 2002 Sep;40(3):300-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12192354&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kelly AM, Kerr D, Powell C. Is severity assessment after one hour of treatment better for predicting the need for admission in acute asthma. Respir Med. 2004 Aug;98(8):777-81. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15303644&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kelly CS, Andersen CL, Pestian JP, Wenger AD, Finch AB, Strope GL, Luckstead EF. Improved outcomes for hospitalized asthmatic children using a clinical pathway. 2000 May;84(5):509-16. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10831004&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kim IK, Phrampus E, Venkataraman S, Pitetti R, Saville A, Corcoran T, Gracely E, Funt N, Thompson A. Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial. Pediatrics. 2005 Nov;116(5):1127-33. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16263999&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Knudson A, Casey M, Burlew M, Davidson G. Disparities in pediatric asthma hospitalizations. J Public Health Manag Pract. 2009 May-Jun;15(3):232-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19363403&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lanphear BP, Aligne CA, Auinger P, Weitzman M, Byrd RS. Residential exposures associated with asthma in US children. Pediatrics. 2001 Mar;107(3):505-11.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lanphear BP, Kahn RS, Berger O, Auinger P, Bortnick SM, Nahhas RW. Contribution of residential exposures to asthma in us children and adolescents. Pediatrics. 2001 Jun;107(6):E98.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lanski SL, Greenwald M, Perkins A, Simon HK. Herbal therapy use in a pediatric emergency department population: expect the unexpected. Pediatrics. 2003 May;111(5 Pt 1):981-5. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12728075&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lara M, Duan N, Sherbourne C, Halfon N, Leibowitz A, Brook RH. Children's use of emergency departments for asthma: persistent barriers or acute  need. J Asthma. 2003 May;40(3):289-99. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12807173&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lavorini F, Fontana GA. Targeting drugs to the airways: The role of spacer devices. Expert Opin Drug Deliv. 2009 Jan;6(1):91-102. [74 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19236210&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lemanske RF Jr, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, Covar RA, Guilbert TW, Larsen G, Morgan WJ, Moss MH, Spahn JD, Taussig LM, Childhood Asthma Research and Education (CARE) Network of the National Heart,. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010 Mar 18;362(11):975-85. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20197425&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Levy M, Heffner B, Stewart T, Beeman G. The efficacy of asthma case management in an urban school district in reducing school absences and hospitalizations for asthma. J Sch Health. 2006 Aug;76(6):320-4. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16918863&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lieu TA, Lozano P, Finkelstein JA, Chi FW, Jensvold NG, Capra AM, Quesenberry CP, Selby JV, Farber HJ. Racial/ethnic variation in asthma status and management practices among children in managed medicaid. Pediatrics. 2002 May;109(5):857-65. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11986447&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mansour ME, Lanphear BP, DeWitt TG. Barriers to asthma care in urban children: parent perspectives. Pediatrics. 2000 Sep;106(3):512-9.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mansour ME. How do we support follow-up with the primary care provider after an emergency department visit for asthma. Pediatrics. 2009 Oct;124(4):1206-7. [9 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19770174&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mark JD. Integrative medicine and asthma. Pediatr Clin North Am. 2007 Dec;54(6):1007-23; xii. [66 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18061788&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Martin J, Donaldson AN, Villarroel R, Parmar MK, Ernst E, Higginson IJ. Efficacy of acupuncture in asthma: systematic review and meta-analysis of published data from 11 randomised controlled trials. Eur Respir J. 2002 Oct;20(4):846-52. [32 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12412674&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mathew JL, Singh M. Metered dose inhaler with spacer in children with acute asthma. Indian Pediatr. 2008 Apr;45(4):295-7. [12 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18451447&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;McCarney RW, Brinkhaus B, Lasserson TJ, Linde K. Acupuncture for chronic asthma. Cochrane Database Syst Rev. 2009;(1)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;McDowell KM, Chatburn RL, Myers TR, O'Riordan MA, Kercsmar CM. A cost-saving algorithm for children hospitalized for status asthmaticus. Arch Pediatr Adolesc Med. 1998 Oct;152(10):977-84. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9790607&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;McMullen AH, Yoos HL, Kitzman H. Peak flow meters in childhood asthma: parent report of use and perceived usefulness. J Pediatr Health Care. 2002 Mar-Apr;16(2):67-72. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11904640&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mitra A, Bassler D, Watts K, Lasserson TJ, Ducharme FM. Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database Syst Rev. 2009;(4)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mohammed S, Goodacre S. Intravenous and nebulised magnesium sulphate for acute asthma: systematic review  and meta-analysis. Emerg Med J. 2007 Dec;24(12):823-30. [39 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18029512&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Moira CY, Ferguson A, Dimich-Ward H, Watson W, Manfreda J, Becker A. Effectiveness of and compliance to intervention measures in reducing house dust and cat allergen levels. 2002 Jan;88(1):52-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11814278&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Morgan WJ, Crain EF, Gruchalla RS, O'Connor GT, Kattan M, Evans R 3rd, Stout J, Malindzak G, Smartt E, Plaut M, Walter M, Vaughn B, Mitchell H, Inner-City Asthma Study Group. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med. 2004 Sep 9;351(11):1068-80. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15356304&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Nakanishi AK, Klasner AK, Rubin BK. A randomized controlled trial of inhaled flunisolide in the management of acute asthma in children. Chest. 2003 Sep;124(3):790-4. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12969999&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007 Nov;120(5 Suppl):S94-138. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17983880&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006 Jan;129(1):15-26. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16424409&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Newman SP. Spacer devices for metered dose inhalers. Clin Pharmacokinet. 2004;43(6):349-60. [77 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15086274&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ng DK, Chow PY, Lai WP, Chan KC, And BL, So HY. Effect of a structured asthma education program on hospitalized asthmatic children: a randomized controlled study. Pediatr Int. 2006 Apr;48(2):158-62. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16635175&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Norton SP, Pusic MV, Taha F, Heathcote S, Carleton BC. Effect of a clinical pathway on the hospitalisation rates of children with asthma: a prospective study. Arch Dis Child. 2007 Jan;92(1):60-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16905562&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Plotnick L, Ducharme F. Combined inhaled anticholinergics and beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev. 2009;(4):CD000060.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Portnoy JM, Jennings D. Utilization patterns in an asthma intervention. 2006 Jul;97(1 Suppl 1):S25-30. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16892768&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Qureshi F, Zaritsky A, Poirier MP. Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma. J Pediatr. 2001 Jul;139(1):20-6.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Qureshi F, Zaritsky A, Welch C, Meadows T, Burke BL. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med. 2005 Jul;46(1):29-36. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15988423&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ralston ME, Euwema MS, Knecht KR, Ziolkowski TJ, Coakley TA, Cline SM. Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. J Emerg Med. 2005 Jul;29(1):29-35. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15961004&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Reznik M, Ozuah PO, Franco K, Cohen R, Motlow F. Use of complementary therapy by adolescents with asthma. Arch Pediatr Adolesc Med. 2002 Oct;156(10):1042-4. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12361452&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ribeiro de Andrade C, Duarte MC, Camargos P. Correlations between pulse oximetry and peak expiratory flow in acute asthma. Braz J Med Biol Res. 2007 Apr;40(4):485-90. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17401491&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Rich M, Lamola S, Amory C, Schneider L. Asthma in life context: Video Intervention/Prevention Assessment (VIA). Pediatrics. 2000 Mar;105(3 Pt 1):469-77.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Rivera ML, Kim TY, Stewart GM, Minasyan L, Brown L. Albuterol nebulized in heliox in the initial ED treatment of pediatric asthma: a  blinded, randomized controlled trial. Am J Emerg Med. 2006 Jan;24(1):38-42. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16338507&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Rodrigo G, Pollack C, Rodrigo C, Rowe BH. Heliox for nonintubated acute asthma patients. Cochrane Database Syst Rev. 2006;(4):CD002884. [29 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17054154&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax. 2005 Sep;60(9):740-6. [47 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16055613&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Rodriguez MA, Winkleby MA, Ahn D, Sundquist J, Kraemer HC. Identification of population subgroups of children and adolescents with high asthma prevalence: findings from the Third National Health and Nutrition Examination Survey. Arch Pediatr Adolesc Med. 2002 Mar;156(3):269-75.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Rosen CM, Rodriguez L. The Inner-City Asthma Intervention asthma counselor program: a collaborative model between physician and social worker to help empower families. 2006 Jul;97(1 Suppl 1):S16-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16892766&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Rowe B, Bretzlaff J, Bourdon C, Bota G, Blitz S, Camargo CA. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database Syst Rev. 2009;(4)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Rowe B, Spooner C, Ducharme F, Bretzlaff J, Bota G. Early emergency department treatment of acute asthma with systemic corticosteroids [Systematic Review]. Cochrane Database Syst Rev. 2009;(1):1.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006 Jun 20;144(12):904-12. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16754916&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Salpeter SR, Wall AJ, Buckley NS. Long-acting beta-agonists with and without inhaled corticosteroids and catastrophic asthma events. Am J Med. 2010 Apr;123(4):322-8.e2. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20176343&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sanghera N, Chan PY, Khaki ZF, Planner C, Lee KK, Cranswick NE, Wong IC. Interventions of hospital pharmacists in improving drug therapy in children: a systematic literature review. Drug Saf. 2006;29(11):1031-47. [26 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17061909&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Scarfone RJ, Capraro GA, Zorc JJ, Zhao H. Demonstrated use of metered-dose inhalers and peak flow meters by children and adolescents with acute asthma exacerbations. Arch Pediatr Adolesc Med. 2002 Apr;156(4):378-83. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11929373&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Schonberger HJ, Maas T, Dompeling E, Knottnerus JA, van Weel C, van Schayck CP. Compliance of asthmatic families with a primary prevention programme of asthma and effectiveness of measures to reduce inhalant allergens--a randomized trial. Clin Exp Allergy. 2004 Jul;34(7):1024-31. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15248845&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Schreck DM, Babin S. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. Am J Emerg Med. 2005 Nov;23(7):842-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16291438&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Schuh S, Dick PT, Stephens D, Hartley M, Khaikin S, Rodrigues L, Coates AL. High-dose inhaled fluticasone does not replace oral prednisolone in children with mild to moderate acute asthma. Pediatrics. 2006 Aug;118(2):644-50. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16882819&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Schulte A, Musolf J, Meurer JR, Cohn JH, Kelly KJ. Pediatric asthma case management: a review of evidence and an experimental study  design. J Pediatr Nurs. 2004 Aug;19(4):304-10. [22 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15308981&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Shalowitz MU, Berry CA, Quinn KA, Wolf RL. The relationship of life stressors and maternal depression to pediatric asthma morbidity in a subspecialty practice. Ambul Pediatr. 2001 Jul-Aug;1(4):185-93.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sin DD, Man SF. Low-dose inhaled corticosteroid therapy and risk of emergency department visits for asthma. Arch Intern Med. 2002 Jul 22;162(14):1591-5. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12123402&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Smith LA, Bokhour B, Hohman KH, Miroshnik I, Kleinman KP, Cohn E, Cortes DE, Galbraith A, Rand C, Lieu TA. Modifiable risk factors for suboptimal control and controller medication underuse among children with asthma. Pediatrics. 2008 Oct;122(4):760-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18829799&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Smith M, Iqbal S, Rowe BH, N'Diaye T. Corticosteroids for hospitalised children with acute asthma. Cochrane Database Syst Rev. 2009;(4)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sockrider MM, Abramson S, Brooks E, Caviness AC, Pilney S, Koerner C, Macias CG. Delivering tailored asthma family education in a pediatric emergency department setting: a pilot study. Pediatrics. 2006 Apr;117(4 Pt 2):S135-44. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16777829&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sole D, Komatsu MK, Carvalho KV, Naspitz CK. Pulse oximetry in the evaluation of the severity of acute asthma and/or wheezing  in children. J Asthma. 1999 Jun;36(4):327-33. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10386496&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Spiegel J, Love AS, Wood PR, Griffith M, Taylor KR, Williams SG, Redd SC. The Inner-City Asthma Intervention: Description of a community-based implementation of an evidence-based approach to asthma management. 2006;97(Suppl 1):S6-10. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16892764&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Travers A, Jones AP, Kelly K, Barker SJ, Camargo CA, Rowe BH. Intravenous beta2-agonists for acute asthma in the emergency department. Cochrane Database Syst Rev. 2001;(2):CD002988. [63 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Vidgren M, Paronen P. Effect of Extension Devices on Drug Deposition from Inhalation Aerosols. Int J Pharm. 1987;39:107-12.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Walders N, Kercsmar C, Schluchter M, Redline S, Kirchner HL, Drotar D. An interdisciplinary intervention for undertreated pediatric asthma. Chest. 2006 Feb;129(2):292-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16478844&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Walters EH, Gibson PG, Lasserson TJ, Walters JA. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev. 2007;(1):CD001385. [299 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17253458&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Walters EH, Walters J. Regular vs. as needed inhaled short acting beta2-agonist use in asthma. The Cochrane Database of systematic reviews. CD001285. In: Cochrane Library [database online]. Issue 2. Oxford: Update Software; 2002&amp;nbsp; &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12804401&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wazeka A, Valacer DJ, Cooper M, Caplan DW, DiMaio M. Impact of a pediatric asthma clinical pathway on hospital cost and length of stay. Pediatr Pulmonol. 2001 Sep;32(3):211-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11536450&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wilson SE, Leonard A, Moomaw C, Schneeweiss S, Eckman MH. Underuse of controller medications among children with persistent asthma in the Ohio medicaid population: evolving differences with new medications. Ambul Pediatr. 2005 Mar-Apr;5(2):83-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15780019&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wolf F, Guevara JP, Grum CM, Clark NM, Cates CJ. Educational interventions for asthma in children. Cochrane Database Syst Rev. 2008;(4)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wood P, Tumiel-Berhalter L, Owen S, Taylor K, Kattan M. Implementation of an asthma intervention in the inner city. 2006 Jul;97(1 Suppl 1):S20-4. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16892767&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wright RO, Santucci KA, Jay GD, Steele DW. Evaluation of pre- and posttreatment pulse oximetry in acute childhood asthma. Acad Emerg Med. 1997 Feb;4(2):114-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9043537&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Yilmaz O, Sogut A, Kose U, Sakinci O, Yuksel H. Influence of ambulatory inhaled treatment with different devices on the duration  of acute asthma findings in children. J Asthma. 2009 Mar;46(2):191-3. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19253129&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Yoos HL, Kitzman H, McMullen A, Henderson C, Sidora K. Symptom monitoring in childhood asthma: a randomized clinical trial comparing peak expiratory flow rate with symptom monitoring. 2002 Mar;88(3):283-91. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11926622&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Zemek RL, Bhogal SK, Ducharme FM. Systematic review of randomized controlled trials examining written action plans  in children: what is the plan. Arch Pediatr Adolesc Med. 2008 Feb;162(2):157-63. [28 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18250241&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Zorc JJ, Chew A, Allen JL, Shaw K. Beliefs and barriers to follow-up after an emergency department asthma visit: a randomized trial. Pediatrics. 2009 Oct;124(4):1135-42. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19786448&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Zorc JJ, Scarfone RJ, Li Y, Hong T, Harmelin M, Grunstein L, Andre JB, Randomized trial. Scheduled follow-up after a pediatric emergency department visit for asthma: a randomized trial. Pediatrics. 2003 Mar;111(3):495-502. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12612227&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Zorc JJ, Scarfone RJ, Li Y. Predictors of primary care follow-up after a pediatric emergency visit for asthma. J Asthma. 2005 Sep;42(7):571-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16169791&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate medical treatment and management of acute asthma exacerbations in children as demonstrated by:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Resolution of acute episode with use of appropriate therapies and decreasing the use of unnecessary therapies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reduced risk of readmission to the emergency department or inpatient unit &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Maintained and improved patient/family satisfaction with treatment &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Dosages in excess of 1 mg/kg of prednisone or prednisolone (sodium succinate) have been associated with adverse behavioral effects in children. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recognized that many children will have problems with treatment adherence due to an oral aversion to medicine, especially bitter-tasting corticosteroid preparations. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Possible side effects of magnesium sulfate to be aware of include hypotension, hypotonia, or abnormal reflexes when given doses above that recommended for asthma. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Acetaminophen has been associated with an increased risk of wheezing. In children &lt;strong&gt;&lt;em&gt;with&lt;/em&gt;&lt;/strong&gt; known aspirin induced asthma (AIA), it is prudent to counsel parents regarding the potential for cross-sensitivities to non-steroidal anti-inflammatory drugs (NSAIDs). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Epidemiological evidence suggests a link between long-acting beta&lt;sub&gt;2&lt;/sub&gt;-agonists (LABAs) and increases in asthma mortality. Concern remains that symptomatic benefit from treatment with LABAs might lead to underestimation of acute attack severity and long-term use could lead to tolerance to their bronchodilator effects. In addition, recent analyses by the Food and Drug Administration (FDA) and others concluded that use of LABAs is associated with an increased risk of severe worsening of asthma symptoms, leading to hospitalization in both children and adults and death in some patients with asthma. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Difference in the reduction of adverse events such as tachycardia, tremor, or increase in blood pressure has not been demonstrated when &lt;span style=&quot;text-decoration: underline;&quot;&gt;equivalent&lt;/span&gt; doses of levalbuterol and albuterol have been studied. The use of racemic albuterol with metered dose inhaler (MDI) has been shown to result in lower pulse rates when compared to nebulizer. This may be an important consideration for children at risk for tachycardia including children with congenital heart disease or known arrhythmias. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Exercise caution in managing children with comorbid conditions such as:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Congenital or acquired cardiovascular disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cystic fibrosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Chronic lung disease or bronchopulmonary dysplasia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Immunodeficiency syndromes &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Long-acting beta&lt;sub&gt;2&lt;/sub&gt;-agonists (LABAs) are contraindicated without the use of an asthma controller medication such as inhaled corticosteroid, and should not be used alone.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;These recommendations result from review of literature and practices current at the time of their formulations. This guideline does not preclude using care modalities proven efficacious in studies published subsequent to the current revision of this document. This document is not intended to impose standards of care preventing selective variances from the recommendations to meet the specific and unique requirements of individual patients. Adherence to this guideline is voluntary. The clinician in light of the individual circumstances presented by the patient must make the ultimate judgment regarding the priority of any specific procedure.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Any available implementation tools are available online and may be distributed by any organization for the global purpose of improving child health outcomes. Web site address: &lt;a href=&quot;http://www.cincinnatichildrens.org/svc/alpha/h/health-policy/ev-based/default.htm&quot; title=&quot;CCHMC Web site&quot;&gt;http://www.cincinnatichildrens.org/svc/alpha/h/health-policy/ev-based/default.htm&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Chart Documentation/Checklists/Forms" /><FieldValue Value="Clinical Algorithm" /><FieldValue Value="Patient Resources" /><FieldValue Value="Quick Reference Guides/Physician Guides" /><FieldValue Value="Resources" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cincinnati Children's Hospital Medical Center. Evidence-based care guideline for management of acute asthma exacerbation in children. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2010 Sep 16. 35 p.  [168 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This following tables and attachments were adapted from the National Heart Blood and Lung Institute, National Education and Prevention Program Expert Panel Report 3: Diagnosis and Management of Asthma, 2007:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Table 1: Aerosolized therapies &amp;ndash; drugs and dosage recommendations &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Table 2: Corticosteroids &amp;ndash; drugs and dosage recommendations &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Table 3: Adjunctive therapies &amp;ndash; drugs and dosage recommendations &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Attachment 3: Formal evaluation of asthma exacerbation severity in ED or urgent care setting &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Attachment 6: How to control what makes your asthma worse &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Attachment 7: How to use your metered-dose inhaler &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="1998 Jul 20 (revised 2010 Sep 16)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Cincinnati Children's Hospital Medical Center - Hospital/Medical Center" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Cincinnati Children's Hospital Medical Center&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Asthma Team 2010&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Community Physicians&lt;/em&gt;: Scott Callahan, MD, Co-Chair (General Pediatrics); William DeBuys, MD (General Pediatrics)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Cincinnati Children's Hospital Medical Center (CCHMC) Physicians&lt;/em&gt;: Carolyn Kercsmar, MD, Co-Chair (Allergy and Pulmonary Medicine); Jeffrey Simmons, MD, Methodologist (General Pediatrics); *Michele Lierl, MD (Allergy and Pulmonary Medicine); Craig Gosdin, MD (General Pediatrics); Laurie Johnson, MD (Emergency Medicine); Sue Poynter, MD (Critical Care Medicine); Rajit Basu, MD (Critical Care Medicine)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Residents&lt;/em&gt;: Angela Statile, MD (Chief Resident); Corrine Bria, MD (Chief Resident)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Nursing&lt;/em&gt;: Sue Wieser, RN; Lisa Crosby, RN&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Pharmacy&lt;/em&gt;: Bradley McCrory, PharmD; Michelle Caruso, PharmD, BCPS&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Respiratory Therapy&lt;/em&gt;: Edward Conway, RRT (Certified Asthma Educator); Lisa Devoto, RN, RT, CPN (Certified Asthma Educator); Rachel Keller, RRT, RPFT (Certified Asthma Educator)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;James M. Anderson Center (AC) - Support&lt;/em&gt;: *Eloise Clark, MPH, MBA (Lead Program Administrator); *Wendy Gerhardt, MSN, RN-BC (Program Administrator); Danette Stanko-Lopp, MA, MPH (Epidemiologist); Karen Vonderhaar, RN, MSN (Program Administrator)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Ad hoc Advisors&lt;/em&gt;: Lorie Ferenzi, (Allergy and Pulmonary Medicine); *Richard Ruddy, MD (Director, Emergency Medicine); *Amal Assa'ad, MD (Allergy); Karen McDowell, MD (Pulmonary Medicine)&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Member of 2002 Development Team&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All Team Members and Anderson Center (AC) Support staff listed have declared whether they have any conflict of interest and none were identified.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Cincinnati Children's Hospital Medical Center. Managing an acute exacerbation of asthma. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2002 Sep 3. 21 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.cincinnatichildrens.org/WorkArea/linkit.aspx?LinkIdentifier=id&amp;amp;ItemID=87871&amp;amp;libID=87559&quot; title=&quot;CCHMC Web site&quot;&gt;Cincinnati Children's Hospital Medical Center&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: For information regarding the full-text guideline, print copies, or evidence-based practice support services contact the Cincinnati Children's Hospital Medical Center Health James M. Anderson Center for Health Systems Excellence at &lt;a href=&quot;mailto:EBDMInfo@cchmc.org&quot;&gt;EBDMInfo@cchmc.org&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Guideline highlights: Acute exacerbation of asthma. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2010 Sep. 1 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.cincinnatichildrens.org/assets/0/78/1067/2709/2777/2793/9199/d0034032-7ddd-4314-9638-340bfad7b31e.pdf&quot; title=&quot;CCHMC Web site&quot;&gt;Cincinnati Children's Hospital Medical Center Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Asthma exacerbation inpatient order set template. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2010. 2 p. Electronic copies: Available from the &lt;a href=&quot;http://www.cincinnatichildrens.org/assets/0/78/1067/2709/2777/2793/9199/3a1e1075-9382-4ea4-ac0c-acc07b434f88.pdf&quot; title=&quot;CCHMC Web site&quot;&gt;Cincinnati Children's Hospital Medical Center&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evidence-based care guideline development and update process. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2006 Mar. 35 p. Available from the &lt;a href=&quot;http://www.cincinnatichildrens.org/svc/alpha/h/health-policy/resources.htm&quot; title=&quot;CCHMC Web site&quot;&gt;Cincinnati Children's Hospital Medical Center Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Judging the strength of a recommendation. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2009 May. 1 p. Available from the &lt;a href=&quot;http://www.cincinnatichildrens.org/assets/0/78/1067/2709/2777/2793/9200/d7344329-03d0-45f3-b6ca-02c746a472ec.pdf&quot; title=&quot;CCHMC Web site&quot;&gt;Cincinnati Children's Hospital Medical Center Web Site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Grading a body of evidence to answer a clinical question. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2009 May. 1 p. Available from the &lt;a href=&quot;http://www.cincinnatichildrens.org/assets/0/78/1067/2709/2777/2793/9200/bd6f4eea-825c-49c3-a0e5-3e66c54dc066.pdf&quot; title=&quot;CCHMC Web site&quot;&gt;Cincinnati Children's Hospital Medical Center Web Site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Table of evidence levels. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2009 May. 1 p. Available from the &lt;a href=&quot;http://www.cincinnatichildrens.org/assets/0/78/1067/2709/2777/2793/9200/5ce396bf-fdcb-4c65-a9f2-1b9888d4fc7e.pdf&quot;&gt;Cincinnati Children's Hospital Medical Center Web Site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Print copies: For information regarding the full-text guideline, print copies, or evidence-based practice support services contact the Cincinnati Children's Hospital Medical Center Health James M. Anderson Center for Health Systems Excellence at &lt;a href=&quot;mailto:EBDMInfo@cchmc.org&quot;&gt;EBDMInfo@cchmc.org&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Also, the attachments to the &lt;a href=&quot;http://www.cincinnatichildrens.org/WorkArea/linkit.aspx?LinkIdentifier=id&amp;amp;ItemID=87871&amp;amp;libID=87559&quot; title=&quot;CCHMC Web site&quot;&gt;original guideline document&lt;/a&gt; contain additional information on evaluating and managing asthma.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The attachments to the &lt;a href=&quot;http://www.cincinnatichildrens.org/WorkArea/linkit.aspx?LinkIdentifier=id&amp;amp;ItemID=87871&amp;amp;libID=87559&quot; title=&quot;CCHMC Web site&quot;&gt;original guideline document&lt;/a&gt; contain information on how to control asthma, how to use a metered-dose inhaler, and how to use a peak flow meter.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Also, there is additional patient resource information available from the &lt;a href=&quot;http://www.cincinnatichildrens.org/health/info/allergy-asthma/default.htm&quot; title=&quot;CCHMC Web site&quot;&gt;Cincinnati Children's Hospital Medical Center Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This summary was completed by ECRI on September 20, 1999. The information was verified by the guideline developer on November 15, 1999. This summary was updated by ECRI on November 26, 2002. The information was verified by the guideline developer on December 24, 2002. This summary was updated on May 3, 2005 following the withdrawal of Bextra (valdecoxib) from the market and the release of heightened warnings for Celebrex (celecoxib) and other nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). This summary was updated by ECRI on June 16, 2005, following the U.S. Food and Drug Administration advisory on COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). This summary was updated by ECRI on December 5, 2005 following the U.S. Food and Drug Administration (FDA) advisory on long-acting beta2-adrenergic agonists (LABA). This NGC summary was updated by ECRI Institute on March 10, 2011. This summary was updated by ECRI Institute on October 28, 2013 following the U.S. Food and Drug Administration advisory on Acetaminophen. This summary was updated by ECRI Institute on September 18, 2015 following the U.S. Food and Drug Administration advisory on non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original full-text guideline, which is subject to the following copyright restrictions:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Copies of this &lt;a href=&quot;http://www.cincinnatichildrens.org/svc/alpha/h/health-policy/ev-based/default.htm&quot; title=&quot;CCHMC Web site&quot;&gt;Cincinnati Children's Hospital Medical Center (CCHMC)&lt;/a&gt; Evidence-Based Clinical Practice Guideline (EBCG) are available online and may be distributed by any organization for the global purpose of improving child health outcomes. Examples of approved uses of CCHMC's EBCG include the following:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Copies may be provided to anyone involved in the organization's process for developing and implementing evidence-based care guidelines. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hyperlinks to the CCHMC website may be placed on the organization's website. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The EBCG may be adopted or adapted for use within the organization, provided that CCHMC receives appropriate attribution on all written or electronic documents. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Copies may be provided to patients and the clinicians who manage their care. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Notification of CCHMC at &lt;a href=&quot;mailto:EBDMInfo@cchmc.org&quot;&gt;EBDMInfo@cchmc.org&lt;/a&gt; for any EBCG adopted, adapted, implemented or hyperlinked to by a given organization and/or user, is appreciated.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
